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Abstract	
 
The gastrointestinal tract in humans is home to 100 trillion bacteria, collectively 
referred to as the gut microbiota. This ‘bacterial organ’ has a vital role to play in 
both health and disease. Conventional wisdom dictates that bile in normal biliary 
systems is sterile. However, the liver is continually exposed to gut bacteria and 
their metabolites via the portal vein. Recent studies have identified bacterial 
populations within the biliary system of symptomatic patients undergoing 
cholecystectomy or biliary intervention. In this study we identified that there is a 
complex biliary microbiota within a normal biliary tract. 
Many bacterial species were isolated from the bile of patients undergoing hepatic 
resection or cholecystectomy and their identity established through sequencing 
their 16S ribosomal RNA gene. These included Staphylococcus, Micrococcus, 
Enterococcus and Bacillus sp.  Isolated bacteria were examined for their 
resistance to bile salts and the results suggested that all the isolates were able to 
survive under physiologically relevant bile concentrations with some isolates 
expressing bile salt hydrolase activity. An in-depth analysis of the biliary 
microbiome using 16S-based metataxonomics was performed. Results 
suggested that human bile has a diverse and varied microbiota, a large 
proportion of which were unculturable. 34 different genera were identified with 
Pseudomonas being the most prevalent. Dysbiosis was noted between diseased 
(e.g. gallstone and biliary obstruction) and normal samples. 
The gut microbiota of the two most common chronic biliary conditions, Primary 
Sclerosing Cholangits and Primary Biliary Cholangitis, were also examined to see 
if dysbiosis was present. There is an emerging dysbiosis in patients with chronic 
cholestatic liver disease, although these results were possibly restricted through 
patient treatment with ursodeoxycholic acid.  
This study is the first to describe a complex biliary microbiota in normal human 
bile and in the future a detailed understanding of the function of this microbiota 
may provide a therapeutic target for biliary disease.  
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1 Introduction	
 
1.1		The	gut	microbiome	in	health	and	disease	
1.1.1 Microbiome	in	health	
 
Over the past decade, the number of publications relating to the human microbiota 
has exponentially risen (Figure 1-1). Early research was reliant on culture 
dependant techniques, which had limitations as many of the bacteria resident in 
the gut are unculturable. However recent developments in metagenomic 
techniques such as high throughput sequencing and 16S rRNA based micro-arrays 
have allowed us to have a full understanding of the vast range of gut bacteria. 
Developments in metabolomics and proteomic techniques have allowed us to gain 
insight into the way that gene expression and microbial proteins shape the way the 
human intestine works. (Ahmad and Akbar, 2016) 
 
Figure 1-1 Number of publications relating to microbiota since 2000. Data obtained by searching PubMed by 
year with the following terms: intestinal microbiota, gut microbiota, intestinal flora, gut flora, intestinal 
microflora and gut microflora. 
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The gastrointestinal tract in humans is home to 100 trillion bacteria with at least 
1000 different bacterial species (Shanahan, 2012).  The number of bacterial cells 
increases throughout the GI tract, rising from 101 per gram of contents in the 
stomach to 1012 cells in the colon (Sekirov et al., 2010). These bacteria contribute 
1.5 – 2Kg to total body weight (Tojo et al., 2014). The neonatal gut is thought to be 
sterile at birth. However, a microbiota similar to that of an adult is readily 
established throughout the first year of life. Factors that influence the colonization 
of the neonatal good include mode of delivery, diet and feeding, sanitation and 
exposure to antibiotics. Once established the microbiota remains static with 
changes due to environmental factors and medications often being transient. 
Indeed, there is some evidence that suggests alteration in the development of the 
microbiota in early life may have a vital role in disease expression in the future. 
The microbiota then remains stable until old age, where changes in diet and 
digestive physiology are thought to lead to changes in the microbiota composition. 
 
Figure 1-2 Distribution of the normal human gut flora. Taken from Jandhyala SM 2015 
The majority of the microbiota is made up of bacteria with eukaryotes and viruses 
also contributing. Although there are more 1000 phylotypes at species-level (Tojo 
et al., 2014) there are 2 dominant phyla that make up 90% of all phylotypes in the 
human gut; Bacteriodetes and Firmicutes. However, there is variability in the 
prevalence of bacterial groups throughout the intestine (Sekirov et al., 2010) (See 
figure 1.2) and great variability at species level between individuals. As more is 
understood about the gut microbiota, three main clusters, or enterotypes, have 
emerged which span individuals and countries (see Table 1-1). Each of these 
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enterotypes have specific mechanisms in which to gain energy from the human 
colon. These enterotypes do not appear to be influenced by diet, age or BMI 
(Arumugam et al., 2011). 
Table 1-1 Main 3 enterotypes in the human colon 
To date there has been limited study into the microbiota of the duodenum. This is 
in part due to the difficulty in obtaining samples in comparison to the colon (Wang 
et al. 2013). However, the duodenum is an important part of the gastro-intestinal 
tract with regards to this thesis as it has a close relationship with the biliary system 
with bile draining directly into it. It lies at a strategic crossroads between the acid-
secreting stomach and nutrient absorbing jejunum/ileum with the duodenal 
microbiota being implicated in diseases such as small bowel bacterial overgrowth, 
coeliac disease and IBS (Li et al. 2015). Li et al discovered that the bacterial 
diversity of duodenal biopsies was as high as rectal biopsies with the predominant 
phyla being Proteobacteria and dominant genera being Acinetobacter, Prevotella 
and Streptococcus (Li et al. 2015). 
The microbiome and host form a symbiotic relationship, with the gut providing a 
stable environment for proliferation with a plentiful supply of growth substrates 
through host diet. In return the microbiota provides energy sources through 
fermentation and production of essential vitamins and amino acids, breaks down 
indigestible food and provides a barrier against invasive pathogenic bacteria. (Le 
Gall et al., 2011; Liu et al., 2013).  
Bacteria rely on undigested carbohydrates from the upper gastro-intestinal tract in 
order to survive. These complex polysaccharides are broken down by bacteria into 
short chain fatty acids including acetate, which other bacteria use as a nutrient 
source, butyrate and propionate, which the host can use as an energy source. 
(Rowland et al., 2017; Laparra and Sanz, 2010). 
Enterotype Predominant Genera Energy Source 
1 Bacteroides  
Parabacteroides 
Carbohydrate and 
Protein degradation 
2 Prevotella     
Desulfovibrio 
Mucin desulfation and 
degradation 
3 Ruminococcus  
Akkermansia 
Mucin degradation and 
simple sugar uptake 
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The gut commensals Bacteroidetes, Propionibacterium, Clostridia, Streptococci, 
Staphylococci and Bacillus have all been shown to have proteolytic properties in 
faecal samples, converting ingested dietary and endogenous protein into shorter 
peptides, amino acids and short chain fatty acids for use by the host (Macfarlane 
et al., 1986).  
The essential vitamins that can be synthesised by the gut microbiota include 
vitamin K and the B group vitamins including biotin, cobalamin, folates, nicotinic 
acid, pantothenic acid, pyridoxine, riboflavin and thiamine (Hill, 1997). Many 
different bacteria are able to synthesise vitamins, with the vast majority of microbes 
from the phyla Bacteroidetes, Fusobacteria and Proteobacteria possessing the 
necessary pathways (Magnúsdóttir et al., 2015). Bacteroidetes appears to have 
the greatest range of vitamin production as well as having the strongest proteolytic 
properties (Rowland et al., 2017), which may explain why deficiencies in this 
phylum are most associated with disease.  
The gut microbiota plays a role in protection against invasion by pathogenic 
bacteria. This is particularly evident in the small intestine where the mucus layer 
that protects the epithelium is discontinuous (Jandhyala et al, 2015). The inter-
play between the microbiota and gut mucosal immune system is a complex one, 
as the gut needs to be tolerant of beneficial commensals whilst also being able to 
resist bacterial pathogens. The ability of gut to differentiate between pathogens 
and commensals is mediated through pattern recognition receptors, in particular 
toll-like receptors (TLR) (Valentini et al, 2014). TLR are activated by microbe-
associated molecular patterns expressed by resident microbiota and result in the 
activation of signalling pathways resulting in production of cytokines, chemokine 
and transcription factors essential for mucosal barrier function and preventing 
infection (Valentini et al. 2014, Jandhyala et al. 2015). Two species that have 
been identified as having key roles in antimicrobial protection are Bacteroides 
thetaiotaomicron and Lactobacillus innocua (Hooper et al. 2003). B. 
thetaiotaomicron is able to induce pathways which result in the cleavage of 
prodefensin to defensin, a cationic antimicrobial peptide which have broad 
spectrum antimicrobial activities against most pathogens (Xie et al. 2014). In 
contrast Lactobacillus species can directly aid the antimicrobial mechanisms of 
the host through production of lactic acid that aids the activity of the host 
lysozyme by disrupting the outer membrane of the bacterial cell wall of invading 
pathogens (Alakomi et el. 2000). 
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The microbiota clearly has a vital role in the development of the host immune 
system. This is demonstrated by mice studies where germ free mice have 
underdeveloped mucosal and systemic immune systems. Interestingly these 
deficiencies can be corrected through colonization with commensal bacteria (Liu 
et al., 2013).   
1.1.2 Microbiome	in	gastrointestinal	disease	
 
Manipulation of the human microbiota in order to prevent or cure disease is not a 
new concept. Clostridium difficile was first discovered as an opportunistic pathogen 
following antibiotic therapy in the 1970’s (George et al., 1978). 20 years later 
eradication of Helicobacter pylori was shown to have a long-term effect on the 
prevention of peptic ulcer disease (Forbes et al., 1994). It is clear that bacteria 
have an important role to play in the health of the human gastro-intestinal tract. 
Despite this it is only fairly recently that treatment aimed at restoring the normal 
microbiota, through faecal microbial transplantation (FMT), has become a 
recognised management strategy for relapse and remitting Clostridium difficile 
infection (CDI) (Borody et al., 2014). The success of FMT and the understanding 
that the human microbiota has a role to play in homeostasis and gut health has led 
to huge developments in the role of this “bacterial organ” and disease. 
1.1.2.1 Inflammatory	Bowel	Disease	(IBD)	and	the	microbiome	
 
Inflammatory bowel disease is a chronic idiopathic inflammatory condition with two 
main sub-types; Crohn’s disease (CD) and ulcerative colitis. The exact 
pathogenesis of IBD remains unclear. It is clear that there is a definite genetic 
precipitant; the highest risk of development of IBD is seen in monozygotic twins 
and the discovery of NOD2 as a susceptibility gene for Crohn’s disease in 2001 
was just the first step in understanding the genetics of IBD with 163 high risk loci 
being identified through GWAS studies (Jostins et al., 2012).  However, this alone 
does not explain the variance in incidence and disease prognosis. Environmental 
factors such as smoking, drugs and pollutants also clearly play a role but again are 
unable to explain the progression of disease. Evidence is beginning to mount that 
IBD results from an abnormal immune response to microbial stimulation in a 
genetically susceptible person. (Abegunde et al., 2016). 
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Changes to the commensal bacteria are well established in Crohn’s disease with 
a reduced biodiversity described in both Western (Manichanh et al., 2006) and 
Eastern populations (Liu et al., 2012) characterised by a reduction in Firmicutes 
and Bacteroidetes and an abundance of Proteobacteria. The fact that these 
changes span different populations suggests that the microbiota probably play as 
important a role as environmental and genetic factors. Even when environmental 
factors such as smoking, alcohol intake, disease stage and treatments such as 
antibiotics and anti-inflammatories are excluded these changes appear to persist.  
Kaakoush et al (2012) studied the faecal microbiota of 19 newly diagnosed Crohn’s 
patients prior to treatment versus 22 age-matched controls. Again, they 
demonstrated a reduction in Firmicutes, in particular Ruminococcaceae, and a 
marked increase in proteobacteriae. They also demonstrated a non-significant 
increase in Bacteroidetes. As well as a reduction in biodiversity there is also a shift 
towards an inflammatory-promoting microbiome. Two examples that epitomise this 
are an abundance of sulphide generating Desulfovibrio species in UC (Rowan et 
al., 2010) and a reduction in the species Faecalibacterium prausnitzii (Sokol et al., 
2008; Sokol, Seksik et al., 2009) that has been shown to have anti-inflammatory 
properties both in vivo and in vitro for colitis models. Esherichia Coli has repeatedly 
been reported in association with ileal CD (Tojo et al., 2014).  
Surgery is a commonplace consequence of medical therapy in IBD with up to 80% 
of Crohn’s patients requiring surgical resection (Ng and Kamm, 2008).  Even 
before the current knowledge of microbiota, it has long been suspected that contact 
between the intestinal mucosa and faecal matter may have a role to play in disease 
recurrence post-operatively (D'Haens et al., 1998). It is now clear that surgery has 
a major impact on the intestinal microbiota and this may have an effect on 
prognosis and recurrence. Mice undergoing an ileo-colonic resection show a 
sustained and significant loss of microbial diversity in the colon. Interestingly, the 
bacterial populations between of luminal contents sampled from the jejunum and 
colon were nearly identical between individiuals 4 weeks post-surgery having been 
diverse prior.  The predominant effects seen are reduction in the phyla 
Bacteroidetes with expansion of the minor phyla Proteobacteria and 
Deferribacteres (Devine et al., 2013).   
It is therefore possible that IBD is a result of invasive pathogen infection, 
subsequent poor clearance and recognition of said pathogen due to a dysregulated 
immune response, and subsequent chronic intracellular infection. Treatment may 
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lead to remission due to clearance of infection but the condition relapses upon 
reinfection.  
More recently treatments looking to re-establish “normal” microbiota have been 
investigated. In particular, faecal microbial transplantation in UC has shown some 
promising results with statistically significant increases in remission rates and 
mucosal healing following FMT. However, in one of these studies responses were 
limited to stool from a single donor, with lesser effects seen from different donors 
implying the existence of “super donors” among human volunteers (Rossen et al., 
2015; Moayyedi et al., 2015) This suggests that it is the composition of the 
microbiome, as well as dysbiosis in the host, that has an important role in mucosal 
health. 
1.1.2.2 Irritable	Bowel	Syndrome	(IBS)	and	the	microbiome	
 
Irritable bowel syndrome is a leading cause for referrals to the gastroenterology 
services in the UK. Up to 49% of lower gastro-intestinal endoscopies are performed 
for IBS related symptoms (Buono et al., 2017). It is categorized by a wide range of 
symptoms such as constipation, diarrhoea, abdominal pain and bloating. However 
endoscopic investigations are often normal. The aetiology and pathophysiology 
remains unclear and due to this, symptoms are often poorly controlled with 
medication. Hypotheses include visceral hypersensitivity, an abnormal brain-gut 
axis, gastrointestinal dysmotility and chronic low-grade inflammation (Ahmad and 
Akbar, 2016) 
In the last few years it has become clear that the microbiota may have a role to 
play in this difficult and complex condition. 
Following an episode of infectious gastroenteritis, the risk of developing IBS is 
increased six fold (Thabane et al., 2007) with up to 36% of patients developing IBS 
after an enteric infection (Spiller and Garsed, 2009). Thus, alterations in 
composition of microbiota as a result of infection may contribute to development of 
symptoms in those individuals who are susceptible. 
Evidence has been produced to show an on-going alteration in microbiota 
composition of IBS patients, when compared to controls, although changes have 
been difficult to quantity and reproduce given the complexity of the condition, the 
wide range of symptoms experienced and the subjective nature of symptoms 
reported. There is a general decrease in bacterial species in IBS, with decreased 
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biodiversity, similar to that seen in UC (Noor et al., 2010).  This seems particularly 
prevalent in diarrhoea predominant IBS where it has been shown that there is 
significant reduction in bacterial richness, in particular there are higher levels of 
Enterobacteriae with a loss of the Faecalibacterium, which is considered to be a 
beneficial microbe (Carroll et al., 2012). Furthermore, there are greater numbers 
of mucosa-associated bacteria per mm of rectal epithelium, predominantly 
Bacteroides and Clostridia, when comparing IBS patients to controls. However, the 
number of Bifidobacteria was reduced in the diarrhoea predominant subgroup, with 
the number of stools per day negatively correlating with the total number of mucosa 
associated Bifidobacteria and Lactobacilli (Parkes et al., 2012).   
1.1.2.3 Colorectal	cancer	(CRC)	and	the	microbiome	
 
Like IBD, there is a strong genetic component in the development of colorectal 
cancer. However, this alone does not account for the development of cancer and 
many environmental factors have been described.  The development of cancer has 
been associated with chronic intestinal inflammation. Indeed, patients with UC 
have an increased relative risk of developing CRC compared to the “normal” 
population depending on how much of the bowel is affected (14.8 whole colon, 2.8 
left sided, 1.7 rectum) (Ekbom et al., 1990).  It need not be pathogenic bacteria 
that are associated with the development of cancer. Mice models have confirmed 
that Bacteroides fragilis can promote release of pro-mitogenic cytokines through 
immune cell activation (Wu et al., 2009). It has long been established there is an 
association between Streptococcus bovis bacteraemia and advanced colonic 
carcinoma (Paritsky et al., 2015).  Both of these bacteria are commensals of a 
“healthy” microbiota and this again highlights the importance of this complex 
system 
Cancer in the colon develops through the adenoma – carcinoma pathway as 
highlighted in Figure 1-3. 
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Figure 1-3 Polyp – Adenoma – Cancer Pathway for development of colonic carcinoma 
It has been shown that the microbiota in stool samples from patients with distal and 
advanced adenomas is altered, with depletion of Ruminococcaceae, 
Clostridiaceae, and Lachnospiraceae families and enrichment in 
Enterobacteriales, Actinomyces and Streptococcus (Peters et al., 2016). There 
have also been changes described in the micro-environment with enrichment of 
Bacteroidetes fragilis, Bacteroides vulgatus, Bifidobacterium longum, Clostridium 
butyricum, Mitosuokella multiacida, Escherichia coli, Enterococcus faecalis and 
Streptococcus bovis in tumour samples and surrounding tissue. (Terzić et al., 
2010). There is a well-established link between Fusobacterium nucleatum, an 
invasive pro-inflammatory anaerobe, and colorectal cancer with this bacterium 
being significantly more abundant in tumour biopsies when compared to matched 
healthy tissue (Castellarin et al., 2012). This bacterium has a direct link to 
tumorigenesis, increasing multiplicity and selectively recruiting tumour infiltrating 
myeloid cells (Kostic et al., 2013). 
 
1.1.3 The	 colonic	 microbiota	 involvement	 in	 non-gastrointestinal	 tract	
disease	
 
It is clear that the gut microbiota may have a role to play in auto-immune, 
inflammatory and functional disorders of the GI tract. However, evidence is 
beginning to emerge that suggests this effect is not only limited to the human 
intestine. How the microbiota may affect the liver and biliary system is covered in 
the next section, but there is some work that implicates the human microbiota in 
other conditions completely outside of the GI tract. 
Normal Epithelium Hyperproliferative Epithelium
Small Adenoma
Large Adenoma
Colonic Carcinoma
Mucosa
Submucosa
Muscularis Propria
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1.1.3.1 Gut-Brain	Axis	
 
Given that the microbiota plays a key role in signalling pathways in the 
development of the host immune system, it has been suggested that it may equally 
play a role in other feedback channels that are crucial for maintaining homeostasis. 
One such proposal was that of a microbiota – gut – brain axis. It is well documented 
that stress and emotion can trigger release of chemicals and hormones from the 
brain that have an effect on gut function such as motility, immunity, mucus 
production and permeability. Equally parasympathetic nerves in the gut send 
transmissions to the parts of the brain, in particular the pituitary gland, influencing 
production of these chemicals. (Carabotti et al., 2015) Therefore, factors 
influencing gut function, such as the microbiota, may have an influence on 
behaviour and possibly even psychiatric health. Mice studies have shown that 
infection with Campylobacter jejuni leads to anxiety-like behaviour with 
concomitant activation of the vagus nerve (Goehler et al., 2005) and transplanting 
the faecal microbiota can also lead to transfer of certain behaviours (Bercik et al., 
2011). Whilst it is likely that effects on the host immune system may have a role to 
play in gut-brain interactions, it is also clear that gut bacteria may have a direct role 
to play through the production of neuroendocrine hormones (Foster et al., 2016) In 
particular it has been shown that dopamine and norepinephrine can be produced 
by gut microbiota in the caecum in quantities large enough to affect host 
neurophysiology (Asano et al., 2012). Two species commonly used as probiotics, 
Bifidobacterium and Lactobacillus, happen to be prolific producers of 
neurochemicals and have been shown to reduce anxiety and depression in mice 
(Bravo et al., 2011) 
1.1.3.2 Endocrine	
 
It has been recognised that many auto-immune conditions are likely to develop as 
a result of an abnormal host response to bacteria or viruses. More recently the gut 
microbiota has been suggested as the infectious trigger in many of these 
conditions. In type 1 diabetes it has been shown that in all stages of the disease, 
from pre-clinical and newly diagnosed to long term, there was increased intestinal 
permeability to the sugar lactulose, suggesting a damaged mucosal barrier (Bosi 
et al., 2006). In autoimmune thyroiditis, it has been shown that there is a 
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disproportionate incidence (40% vs 5% of the control group) of histological 
lymphocytic colitis, a condition associated with diarrhoea and increased 
intraepithelial lymphocytes. (Cindoruk et al., 2002). Equally in the small bowel there 
are differences in the structure of the microvilli of the small bowel in Type 1 
diabetes and autoimmune thyroiditis (Sasso et al., 2004). 
1.1.3.3 Asthma	
 
There is good epidemiological evidence that early exposure to microorganisms is 
associated with decreased incidence of atopy and childhood asthma (Ege et al., 
2011). The naso-pharynx and GI tract are closely linked with even small volumes 
entering through the nose ending up in the GI tract. Mice studies have shown that 
subjects whose microbiota is altered can develop allergic airways responses to 
allergens (Noverr and Huffnagle, 2005). Additionally, the human microbiota of 
patients with asthma have been shown to differ from normal subjects even prior to 
the development of atopy. (Lynch, 2016) As in Crohn’s disease, the use of 
antibiotics in early life has been shown to be linked to the development of asthma. 
(Shreiner et al., 2008) 
1.1.3.4 Rheumatoid	Arthritis	
 
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterised 
by erosive synovitis affecting the small joints of hands, wrists and feet (Diamanti et 
al., 2016). In early rheumatoid arthritis, there are significant differences in the 
microbiome with a lower abundance of Bifidobacteria and Bacteroides when 
compared to controls with fibromyalgia (Vaahtovuo et al., 2008) again mimicking 
changes seen in IBD. In established RA, there is a decrease in gut microbial 
biodiversity that correlates with disease duration and antibody levels. This study 
also demonstrated expansion of the phyla Acintobacteria; predominantly due to 
increased abundance of the rare genera Collinsella and Eggerthella (Chen et al., 
2016). Collinsella is positively correlated with serum cholesterol levels, has an 
association with insulin resistance and is known to have bile salt hydrolase activity 
(Lahti et al., 2013). 
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1.1.3.5 Obesity	and	the	metabolic	syndrome	
 
Obesity is rapidly becoming a worldwide pandemic with up to 27% of people being 
obese in the UK currently, with a projected prevalence of 50% by 2050. (Public 
Health England, 2017). The metabolic syndrome is a collective medical term for 
the combination of increased blood pressure, increased blood glucose, central 
obesity and elevated cholesterol which occur together and increase an individual’s 
risk of coronary artery disease, type 2 diabetes and stroke.  
It is now clear that long -term diet can affect the microbiota, with high fat and protein 
diet being associated with enterotype 1 whereas diets high in carbohydrate are 
associated with enterotype 2 (Wu et al., 2011). Although this may suggest that diet 
is affecting microbiota, and obesity is a result of high calorie intake, it has been 
shown in mouse models that transferring a microbiota from obese mice fed a high 
fat diet to germ free mice also resulted in the transfer of an obese phenotype 
(Delzenne et al., 2013). This should not come as a surprise however, given that 10 
years earlier Backhed et al (2004) showed that introducing a microbiota from the 
caecum of conventional mice to germ free mice resulted in a 60% increase in body 
weight. Furthermore, the same group showed that GF mice did not gain weight 
even when exposed to a high fat, high sugar diet. (Bäckhed et al., 2007).  
The microbiota is thought to influence body weight through production of short 
chain fatty acids and fermentation of indigestible carbohydrates, which have both 
pro obesity and protective properties (Machado and Cortez-Pinto, 2016). 
Microbiota also influence expression of factors that can increase uptake of fatty 
acids in the adipose tissue and liver, promoting steatosis. Microbiota can also 
increase mucosal blood flow, thereby increasing nutrient absorption. 
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1.2 Liver	disease	
1.2.1 Liver	and	biliary	system	in	health	
 
The liver is the largest internal organ in the body. It receives 25% of the resting 
cardiac output of humans via the portal vein and hepatic artery. Its major roles are 
protein, carbohydrate and lipid metabolism, bile secretion, bile acid metabolism, 
drug and hormone inactivation, storage of essential nutrients and minerals and 
maintenance of host immunity. 
The liver is responsible for the synthesis of the vast majority of circulating proteins 
in the human body.  These include albumin, transport and carrier proteins, acute 
phase proteins and coagulation factors. It is also responsible for degradation of 
proteins. 
The liver maintains blood glucose through the storage of glycogen and the release 
of glucose either through breakdown of glycogen or synthesizing glucose in the 
immediate fasting state.  
Lipids are insoluble in water and therefore are transported in human plasma in 
protein-lipid complexes known as lipoproteins. The liver synthesises two types of 
lipoproteins – high-density lipoprotein (HDL) and very low-density lipoprotein 
(VLDL). It also forms triglycerides from free fatty acids and synthesizes cholesterol 
(Kumar and Clark, 2016). 
The liver is the major site of drug metabolism. It is mediated by a group of enzymes 
comprising the cytochrome P450 system and cytochrome C-reductase. 
Metabolism occurs in 2 stages; firstly, the drug is inactivated through oxidation or 
demethylation (first pass metabolism) and then made water soluble through 
conjugation with glucuronide or sulphate (second pass metabolism). These drugs 
can then be excreted in the bile or urine (Tomankova et al., 2017). 
The liver is also the target organ for many hormones such as insulin. The liver 
catabolises many hormones, such as glucagon, growth hormone, parathyroid 
hormone and glucocorticoids, making them inactive. 
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Figure 1-4 The human biliary system 
The biliary system is a complex arrangement of tubes that carries bile through the 
liver and out to the small intestine. Bile produced by liver cells is secreted into 
microscopic canals known as canaliculi. These then drain into ductules and larger 
ducts within the portal tracts. These then combine to form the left and right hepatic 
ducts that drain each lobe of the liver. These ducts then join at the porta hepatis to 
form the common bile duct hepatic duct. The gallbladder lies just inferior to the 
right lobe of the liver and drains into the cystic duct. These ducts then combine to 
form the common bile duct, which drains into the duodenum. The gallbladder 
concentrates hepatic bile, which it then excretes when food passes into the 
duodenum in order to aid digestion (Kumar and Clark, 2016). 
Bile is made up of water, bile acids, cholesterol, phospholipids and conjugated 
bilirubin.  The liver produces approximately 600ml of bile each day. In the fasted 
state, approximately half of this is diverted to the gallbladder where up to 90% of 
the water is absorbed by the mucosa. When food containing fat reaches the 
duodenum the gallbladder releases this concentrated bile to aid digestion through 
emulsification of fat into smaller molecules which are more readily digested. This 
is predominantly done by bile acids. Bile acids are actively reabsorbed in the 
terminal ileum and recirculated through the enterohepatic circulation. The 
molecular aspects of bile acid synthesis/reabsorption are complex involving the 
farsenoid X receptor, the liver x receptor and the liver receptor homologue. These 
pathways are highlighted in figure 1.5. Approximately 20% are excreted in the 
faeces and replenished through hepatic synthesis (Berne and Levy, 1996). Bile 
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acids are synthesised in the liver from cholesterol. Initially the liver synthesizes the 
primary bile acids cholic acid and chenodeoxycholic acid, which are then 
‘conjugated’ through the addition of either a glycine or taurine to a side chain of 
these bile acids. 
Bile also has a role to play in excretion of waste products from the body, in 
particular bilirubin, phospholipids and cholesterol. Phospholipids, in the form of 
lecithin, and cholesterol are insoluble in water. However, they are able to dissolve 
in bile acid micelles and therefore can be excreted in the stool (Bowen R. 2017). 
 
Figure 1-5 The molecular mechanisms of the enterohepatic circulation. Bile acids act as ligands for FXR, 
which regulates transcription by binding as a heterodimer with RXRs. This step results in increased SHP 
expression. SHP in turn inhibits LRH-1, preventing the activation of target genes that participate in bile acid 
and fatty acid synthesis. In the absence of bile acids, LRH-1 acts together with LXR to stimulate bile acid 
synthesis]. The important pathways in the intestine that contribute to modulation of bile acid synthesis are 
also depicted. There is a bile-acid-mediated activation of intestinal FXR and, as a result, the release of FGF15 
in the small intestine. The secreted FGF15 by the intestine circulates to the liver, likely through the portal 
circulation or lymph flow and induces the activation of FGFR4 in the liver. The FGF15/FGFR4 pathway 
synergizes with SHP in vivo to repress CYP7A1 expression. Bas: bile acids; FGF: fibroblast growth factor; 
FGFR4: FGF receptor; FXR: farnesoid X receptor; LRH-1: liver receptor homologue-1; LXR: liver X receptor; 
RXR: retinoid X receptors; SHP: short heterodimer partner. Adapted from Garruti et al 2012. 
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1.2.2 Microbiota	and	Bile	Salts		
 
The human GI tract has several mechanisms by which it protects itself from enteric 
infections. One of these is the excretion of 3 bactericidal agents; gastric secretions, 
hydrochloric acid and bile. Gastric secretions and hydrochloric acid reduce the pH 
of the stomach to 3 (Merritt and Donaldson, 2009). The high acidity of gastric juice 
kills most ingested microorgansims (Berne and Levy, 1996) This is supported by 
the fact that mice with low gastric acid secretion are more prone to infections by 
Yersinia, Citrobacter, Clostridium and Salmonella (Tennant et al., 2008).  
Bile, or more specifically bile salts, are thought to have bacteriostatic and 
bactericidal properties (Percy-Robb and Collee, 1972). The theory that bile 
protects against pathogenic bacteria stems from the fact that relatively speaking 
the small intestine, which contains a large amount of bile acids, typically contains 
very few bacteria. In conditions associated with impaired bile secretion, such as 
cirrhosis, small bowel bacterial overgrowth is a common feature (Lorenzo-Zúñiga 
et al., 2003). 
There are multiple mechanisms through which bile salts are thought to exert an 
anti-bacterial affect. The primary effect is through disruption of cell membranes. At 
high concentrations, bile salts dissolve cell membranes causing leakage of cell 
contents and instantaneous cell death. At lower concentrations, they have more 
subtle effects on membrane permeability and fluidity.  Unconjugated bile salts are 
also thought to have a more potent bacteriocidal effect. They are more readily able 
to pass through the bacterial lipid bilayer wall, as they are more able to dissolve in 
water (Begley et al., 2005). Additional effects of bile salts include induction of 
secondary structures in RNA, inducing DNA damage and activating enzymes 
involved in DNA repair, causing misfolding and denaturation of proteins, inducing 
oxidative stress and creating low intracellular iron and calcium through metal 
chelation (Kristoffersen et al., 2007; Merritt and Donaldson, 2009; Taranto et al., 
2003).  
Bile acids may also promote antimicrobial effects directly on the host further down 
the GI tract. Conjugated bile causes activation of the farsenoid X receptor in the 
terminal ileum. (Hofmann and Eckmann, 2006) As a result genes, involved in the 
biosynthesis of products associated with mucosal defence in the intestine are 
upregulated: iNOS, IL18 and Angiogenin (Inagaki et al., 2006). iNOS produces 
Nitric Oxide which has direct antimicrobial effects and also promotes mucus 
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secretion, vascular tone and epithelial barrier function. The cytokine IL18 is known 
to stimulate resistance to bacteria and has a role in the early acute phase of 
mucosal inflammation. Angiogenin is part of the acute phase response to infection 
and has direct antibacterial properties. 
Despite the potent antibacterial effects of bile acids, the microbiota has adapted to 
utilise bile salts, which may have an important role in disease. It is now clear that 
the gut microbiota is solely responsible for production of the secondary bile salts 
deoxycholic acid and lithocholic acid through deconjugation, oxidation and 
subsequently dehydroxylation of primary bile salts (Hofmann, 1999). The 
mechanisms through which bacteria transform bile salts is discussed in section 
1.3.6. The vast majority (around 95%) of primary bile salts are reabsorbed in the 
terminal ileum. Around 400-800 mg of primary bile salts pass through to the colon 
where a large proportion undergoes transformation by gut bacteria. This then 
allows these secondary bile acids to be passively reabsorbed and enter the 
enterohepatic circulation (Ridlon et al., 2006). These secondary bile acids have 
roles in both health and disease. Lithocholic acid is toxic to hepatocytes and has 
been linked to colon carcinogensis (Gérard, 2013). Deoxycholic acid has a role to 
play in the formation of the cholesterol gallstone and has been shown to promote 
secretion of pro-tumorigenic factors in hepatocellular carcinoma (Ridlon et al., 
2014). Conversely the production of the secondary bile acid ursodexycholic acid is 
thought to be chemopreventive and is used in the treatment of gallstones and 
primary biliary cirrhosis (Gérard, 2013). Equally the dysbiosis seen in inflammatory 
bowel disease leads to decreased deconjugation and desulfation of the bile acid 
pool which may promote chronic inflammation (Gérard, 2013) 
Therefore, the relationship between bile acids and microbiota is complex and any 
change in the homeostatic mechanisms may result in a shift from gut health to gut 
disease. 
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1.2.3 Chronic	parenchymal	liver	disease	
 
Chronic parenchymal liver disease relates to conditions that affect the actual liver 
cells as opposed to supporting structures. There are a wide range of conditions 
that can lead to chronic liver disease, be it infectious, autoimmune, metabolic or 
toxic (alcohol, drugs). Unlike other systems such as cardiac or respiratory, which 
are falling, the mortality rates in chronic liver disease are continuing to rise. The 
leading causes of chronic parenchymal liver disease are viral hepatitis (B and C), 
alcohol, and non-alcoholic fatty liver disease (Sanyal AJ, 2010). 
Chronic liver disease is a progressive condition leading from normal liver 
architecture to fibrosis and subsequently cirrhosis (Garcia-Tsao et al, 2009). 
Cirrhosis can be defined as a liver diffusely affected by fibrosis and the formation 
of structurally abnormal parenchymal nodes. Fibrosis occurs through inflammation 
and necrosis activating Kupffer cells. These in turn activate stellate cells within the 
liver that reside in the subendothelial space of Diss between sinusoids and 
hepatocytes. The activation of stellate cells leads to increased production and 
deposition of fibrocollageous tissue, which causes irregular scarring. Damaged 
hepatocytes also attempt to regenerate, forming irregular nodules that have 
abnormal relationships with the surrounding vasculature and bile ductules. In the 
early stages of cirrhosis these hepatocytes are able to meet normal demands and 
synthetic function is near normal, but as cirrhosis progresses these demands are 
not met and the symptoms of decompensated liver disease manifest themselves. 
There are 5 main complications of cirrhosis as summarised in Table 1-2. Once 
cirrhosis develops it is irreversible. However, the prognosis is still highly variable 
and is dependent on aetiology, presence of complications, and synthetic function. 
In general, 5-year survival is approximately 50%, but it can be as low as 3 
months if synthetic function is impaired (Fortune & Cardenas, 2017). 
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Table 1-2 Complications of cirrhosis 
The normal pressure within the portal vein is 5-8 mmHg. Portal hypertension 
develops when the portal pressure rises above 10 mmHg. In cirrhosis, this occurs 
as a result of increased vascular resistance due to mechanical distortion in liver 
architecture, increased production of the potent vasoconstrictor endothelin-1, 
decreased production of nitrous oxide in the liver and increased portal inflow as a 
result of splanchnic vasodilatation (Schwabl & Laleman, 2017). Portal hypertension 
is maintained through sodium retention and increased plasma volume (Fortune & 
Cardenas, 2017). The result of portal hypertension is the development of collateral 
blood vessels, known as varices, with the systemic venous circulation. Varices can 
develop at the gastro-oesophageal junction (GOJ), cardia of the stomach, anal 
canal, falciform ligament of the liver, abdominal wall and spleen (Garcia-Tsao et 
al., 2009). The most important of these are GOJ and gastric varices as they tend 
to be close to the mucosal surface and liable to rupture. 90% of patients with 
cirrhosis will develop varices over 12 years. Up to 50% of patients with varices will 
have an episode of bleeding, which is often life threatening. Despite improvements 
in emergency care, endoscopic therapy, radiological therapies and ITU care 6-
week mortality from an index bleed is still around 20%. 
Ascites is defined as the accumulation of free fluid in the peritoneal cavity. The 
leading cause of ascites is cirrhosis, accounting for 75% of cases. Ascites develops 
as a result of portal hypertension, hypoalbuminaemia and salt/water retention due 
to activation of the renin-angiotensin system which in turn occurs as a result of 
renal hypoperfusion following splanchnic pooling. The development of ascites is 
associated with 50% mortality within 2 years and is an indication for liver 
transplantation. Ascites can be complicated by spontaneous bacterial peritonitis. 
The condition is thought to occur due to bacterial translocation, which is discussed 
in section 1.3.1 (Cesaro et al., 2011). It is important as it has a mortality of 20% 
despite improving recognition and treatment. It occurs in 10 to 30% of patients with 
ascites and will re-occur in more than 2/3rds in the first year (Fortune & Cardenas, 
2017). 
Complications of Cirrhosis 
Portal hypertension and variceal haemorrhage 
Ascites 
Encephalopathy 
Hepatocellular Carcinoma 
Renal Failure 
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Hepatorenal syndrome (HRS) is a diagnosis of exclusion and is defined as acute 
kidney injury in a patient with advanced liver disease without an identifiable cause. 
Type 1 HRS refers to a rapid deterioration in renal function, often in relationship to 
an acute decompensating liver injury. Type 2 HRS is a more slowly progressive 
kidney failure in the presence of ascites and sodium retention. The prognosis of 
HRS is exceptionally poor with a median survival of 3 months if treated.  Like many 
complications of cirrhosis it occurs as a result of splanchnic vasoldilation, resulting 
in activation of the renin-angiotensin pathway promoting renal vascoconstriction. 
Reduced cardiac output and release of compounds known to affect renal 
circulation including endothelin-1 are also likely to play a role. (EASL Clinical 
Practice Guidelines, 2010) 
Encephalopathy refers to a chronic neuropsychiatric condition characterised by 
disturbance in sleep – waking patterns, personality changes, confusion and 
impaired levels of consciousness. It is thought to occur as a result of shunting of 
portal blood to the systemic circulation, thereby bypassing the metabolic functions 
of the liver. This means the brain is exposed to nitrogen containing compounds, 
especially ammonia (see section 1.3.1). Encephalopathy is he second commonest 
cause for admission to hospital in patients with cirrhosis and has a huge economic 
burden (Piotrowski & Boroń-Kaczmarska, 2017). Encephalopathy is associated 
with a poor prognosis is an independent predictor of mortality in cirrhosis (Patidar 
and Bajaj, 2015). 
Hepatocellular carcinoma is now the second leading cause of cancer death 
worldwide and its incidence is rapidly rising. Up to 90% of patients with HCC have 
a background of chronic liver disease, usually secondary to hepatitis B/C or 
alcohol, although cirrhosis due to any aetiology can increase the risk. (Sanyal et 
al., 2010) 
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1.2.4 Biliary	diseases	and	complications	
 
The most common disease of biliary tract are gallstones with a prevalence of 10-
20% (Li et al., 2017). In the Western world, around 80% of these are cholesterol 
based. Risk factors include over-eating, low activity, obesity, metabolic syndrome 
and insulin resistance (Paumgartner, 2010). The vast majority of gallstones are 
asymptomatic (Li et al., 2017). However, they can give rise to pain and 
cholecystitis; inflammation and infection of the gallbladder, which can be acute or 
chronic (Rawls, 1971). If left untreated gallstones can migrate into the common bile 
duct and cause obstructive jaundice (Lee et al., 2016) or pass through to the 
intestine and cause gallstone ileus (Glenn, 1967). Other complications include 
cholecystoduodenal fistula (Aguilar-Espinosa et al., 2017) and pancreatitis, which 
can be fatal (Rawls, 1971). Treatment is generally surgical removal of the 
gallbladder or endoscopic removal of biliary stones. 
 
Primary biliary cholangitis (PBC) is a slowly progressive chronic liver disease 
characterized by intrahepatic bile duct destruction, cholestatic liver biochemistry 
and positive auto-antibodies (Marchioni Beery et al., 2014). The prevalence of 
primary biliary cirrhosis has been increasing over the past 30 years and is now a 
significant cause of liver morbidity and mortality (Bowlus et al., 2016). The aetiology 
remains unclear although there is a clear auto-immune and genetic component as 
suggested by a weak association with HLA-B8, the discovery of 12 new 
susceptibility loci on genome-wide association studies (Mells et al., 2011), its 
association with extra hepatic autoimmune disease and a high concordance rate 
in monozygotic twins (Selmi et al., 2011).   
 
Several infectious and environmental factors are thought to contribute to the onset 
of PBC, as evidenced by clustering of cases near toxic waste sites in New York, 
the significantly higher rate of urinary tract infections in patients with PBC (Varyani, 
West, & Card, 2011) and the demonstration of molecular mimicry between 
mitochondrial and nuclear auto antigens in PBC (Shimoda et al., 2003). Given that 
PBC is a chronic inflammatory disorder it is possible that exposure to bacteria in a 
genetically susceptible individual may precipitate the development of the condition. 
Both pathogenic and non-pathogenic Gram-negative bacteria have been proposed 
but as yet not substantiated (Selmi et al., 2011). Through this study, it may be 
possible to detect changes in the human microbiome in PBC patients which may 
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provide further evidence to an infectious cause. At present treatment options for 
PBC are limited.  
 
Ursodeoxycholic acid (UDCA) is the only treatment that has approval, but studies 
have shown that although it improves liver biochemistry and histological 
progression, it may have no effect on mortality, progression to liver transplantation 
or symptoms (Rudic, Poropat, Krstic, Bjelakovic, & Gluud, 2012). If a link between 
the gut microbiota and primary biliary cirrhosis can be established then it may open 
doorways to novel treatment strategies which could prevent and possibly treat 
established disease. 
 
Primary sclerosing cholangitis (PSC) is an autoimmune condition characterized by 
chronic inflammation, progressive fibrosis and stricturing of the intra and extra 
hepatic ducts (Marchioni Beery et al., 2014). It is a slowly progressive disease with 
a median time to liver transplant or death ranging between 12 and 18 years (Yimam 
and Bowlus, 2014). As well as progression to end stage liver disease, PSC is also 
associated with a greatly increased risk of cholangiocarcinoma (Ehlken et al., 
2017). Like PBC the exact aetiology is unknown. It has a definite link with 
inflammatory bowel disease with up to 83% of PSC patients in Northern Europe 
having concurrent IBD (Folseraas et al., 2012). There is also a definite genetic 
susceptibility with a strong association with HLA haplotypes and serum auto-
antibodies (Pollheimer et al., 2011). Up to 40 genetic loci being identified as high 
risk for PSC (Karlsen and Boberg, 2013). Equally 25% of patients have at least 
one other autoimmune condition outside of the colon and liver (Folseraas et al., 
2012). There are no current effective treatments for PSC. UDCA can improve liver 
biochemistry but has no effect on morbidity and mortality (de Vries and Beuers, 
2017). Antibiotics seem to be of benefit, improving liver biochemistry and 
symptoms in patients, especially those without cirrhosis. However, the long-term 
effects are unclear (Davies et al., 2008). It is therefore possible that bacteria may 
have a role to play in the development and progression of PSC. 
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1.3 Liver	disease	and	microbiota 
1.3.1 	Complications	of	cirrhosis	and	barrier	dysfunction	
 
The liver receives 70% of its blood supply directly from the gastrointestinal tract via 
the portal vein. This results in continual exposure to gut bacteria and bacterial cell 
components and metabolites (Son et al., 2010). It is therefore conceivable that this 
complex gut microbiome has an important role in the development of chronic liver 
disease via this “gut-liver axis” and recent research has begun to explore this 
hypothesis. 
Many complications of cirrhosis can be linked to bacterial translocation from the 
gut to mesenteric lymph nodes or other organs (Cesaro et al., 2011). Indeed it is 
felt that spontaneous bacterial peritonitis, high rate of infections in cirrhotics and 
hepatic encephalopathy occurs as a result of bacterial translocation, increased 
intestinal permeability and changes in faecal microbiota (Chen, Yang et al. 2011; 
Wiest, Krag et al. 2012; Tsiaoussis et al., 2015). Intestinal permeability in cirrhosis 
may develop as a result of microbiota alterations leading to increased endotoxin 
production and alterations in tight junction expression and integrity (Pijls et al., 
2013). Equally intestinal permeability may develop as a direct result of portal 
hypertension with a significant correlation between portal pressure, intestinal 
permeability and plasma levels of inflammatory cytokines and LPS being reported 
(Reiberger et al., 2013).  Bacterial translocation may also be promoted through 
small bowel bacterial overgrowth, which develops in cirrhosis as a result of 
prolonged gut transit and disturbances in small bowel manometry (Kalaitzakis, 
2014). 
One of the most disabling complications of cirrhosis is hepatic encephalopathy and 
small bowel bacterial overgrowth is associated with development of this condition 
(Zhang et al., 2016). Equally one of the most effective treatments for 
encephalopathy is the poorly absorbed antibiotic Rifaximin which has a broad 
spectrum of antibacterial activity against both aerobic and anaerobic Gram positive 
and Gram negative bacteria (Garcovich et al., 2012).  
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1.3.2 Non-alcoholic	steatohepatits	(NASH)		
 
One of the complications of obesity and the metabolic syndrome is the 
development of non-alcoholic steatohepatitis (NASH). NASH refers to fatty liver 
disease with associated inflammation and fibrosis and in 2013 accounted for 10% 
of all liver transplants. It is projected to be the leading indication for liver transplant 
in the next few years. It has been shown that young patients with NASH have a 
distinct microbiome from healthy subjects, with a rise in Bacteriodetes and fall in 
Firmicutes. The same study also showed that although there were similarities 
between obese and NASH patients, the latter have statistically significant 
increases in the prevalence of Escherichia. Interestingly these are alcohol 
producing bacteria, which may provide a mechanism through which gut microbiota 
can cause liver inflammation (Zhu et al., 2013). As with a lot of microbiota studies 
these results tend to vary between studies with another group showing 
Bacteroidetes were reduced and Firmicutes, especially lactobacillus, were 
increased in obese patients with non-alcoholic fatty liver disease. They did not 
demonstrate an increase Escherichia or faecal ethanol. These patients however 
were not biopsied and so the degree of liver disease was not determined (Raman 
et al., 2013)  
Although there is no consensus currently on the “typical” NASH microbiota, it is 
clear that changes in the composition of the bacteria described in different studies 
of NASH could potentially have an effect on hepatic inflammation. As well as 
Escherichia sp, several lactobacillus species and Ruminococcus are able to 
produce ethanol and other toxic products such acetate through fermentation. 
Ruminococcaceae produce the fatty acid butyrate, which can decrease gut 
permeability and regulate insulin resistance. A decrease in Gammaproteobacteria 
and increase in Erysipelotrichi has been shown to have a positive predictive value 
for development of fatty liver disease following a choline deficient diet (Spencer et 
al., 2011). Finally, an increase in Bacteroides may lead to an increase in 
deoxycholic acid, which can induce apoptosis in hepatocytes and is known to be 
increased in NASH. 
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1.3.3 Alcoholic	Liver	Disease		
 
Alcohol is the leading cause of end stage liver disease in the Western world. 
However, only a small proportion of people who drink alcohol to excess develop 
cirrhosis (Tuomisto et al., 2014). It is possible that a combination of genetic 
susceptibility to bacterial products (Järveläinen et al., 2001), disruption of mucosal 
barrier by alcohol (Basuroy et al., 2005) and increased rates of bacterial 
translocation (Steffen et al., 1988) may lead to development of fibrosis and 
cirrhosis in alcoholic liver disease. A change in the composition of the gut 
microbiota so that more “harmful” bacteria are prevalent may also play a part. In 
this regard chronic alcohol abuse is associated with decreased numbers of 
Clostridium and Bacteroidetes and increased numbers of Proteobacteria (Mutlu et 
al., 2012). It has been shown that at autopsy there is an increased abundance of 
Entereobactericaea DNA in the liver of cirrhotic patients when compared to non-
cirrhotic controls, although this did not reach statistical significance. However, 
expression of CD14, a bacterial recognition receptor, was associated with the total 
bacterial DNA (Tuomisto et al., 2014). 
1.3.4 Other	Parenchymal	liver	disease	
 
Hepatitis B and C remain one of the leading causes of end stage liver disease and 
hepatocellular carcinoma (HCC). worldwide (Serigado et al., 2017). The degree of 
liver disease related to viral hepatitis may be influenced by the gut microbiota. 
Sandler et al (2011) demonstrated higher plasma levels of bacterial 
lipopolysaccharide (LPS) and soluble CD14 in patients with hepatitis B and C, with 
increasing circulating levels depending on severity of fibrosis. This suggests that 
the degree of liver disease in patients with Hepatitis B and C is associated with 
microbial translocation (Sandler et al., 2011). Conversely, the gut microbiota is also 
involved in immunity with mice studies showing that a gut microbiota is required to 
clear Hepatitis B virus (Chou et al., 2015). 
Viral hepatitis and cirrhosis are the main risk factors for development of 
hepatocellular carcinoma. It is now emerging that the gut microbiota may also 
contribute to development of HCC. Bacterial translocation seems to have a major 
role to play with reduction in LPS through antibiotic treatment reversing dysbiosis, 
decreasing tumour growth and preventing tumour multiplicity in a mice model 
(Zhang et al., 2012). Further rat studies have shown that gut-sterilization in 
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advanced liver disease reduced tumour growth (Dapito et al., 2012). Therefore, it 
is possible that manipulation of the gut microbiota may prevent HCC and delay 
progression to advanced liver disease. 
 
1.3.5 Biliary	disease	and	gut	microbiota	
 
Conventional wisdom dictates that bile is sterile, partly because bile has 
bactericidal effects but also because traditional research has failed to grow 
bacteria from bile (Nielsen, 1976). However, improvements in metagenomics such 
as next generation sequencing and new surgical procedures now mean it is 
possible to perform microbiome analysis on human bile. As a result, there is now 
clear evidence that the diseased human biliary tract has a microbiota. 
It has been established that cholesterol gallstones contain bacteria (Monstein et 
al., 2002) and bacteria including H. pylori has been detected within the mucosa of 
diseased gallbladders (Griniatsos et al., 2009) More recently studies have 
identified a diverse bacterial community within the bile of gallstone patients (Wu et 
al., 2013) and within diseased pancreatic ducts and biliary stents (Swidsinski et al., 
2005). A large case series in Austria found 973 bacterial isolates from 249 patients 
undergoing ERCP for biliary disease. In total only 13% of patient samples were 
sterile (Hakalehto et al., 2010) To date however, no studies have been able to 
assess bile from patients not known to have biliary infection, biliary disease or 
biliary intervention. 
 
Recently bacteria have been grown from the gallbladder bile and mucus layer of 
healthy pigs. Subsequent 16S rRNA gene analysis also confirmed a diverse 
microbiome consisting predominantly of Proteobacteria, Firmicutes and 
Bacteroidetes (Jimenez et al., 2014). 
 
The pathogenesis of hepatobiliary diseases such as PBC and primary sclerosing 
cholangitis are thought to include an infectious trigger (Pollheimer, Halilbasic, 
Fickert, & Trauner, 2011) although studies have failed to show any significant 
bacteriaemia in mesenteric and peripheral blood samples (Weismuller et al, 2008). 
The immune response in PBC is restricted to the epithelial cells of the intrahepatic 
ducts (Selmi, Bowlus, Gershwin, & Coppel, 2011). Therefore, a direct interaction 
between bile duct and bacteria may be the trigger for auto-immune disease. 
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The human biliary tract appears to be programmed for the possible presence of 
bacteria in that biliary epithelial cells express a wide range of innate immune 
receptors that mediate the signalization pathways that initiate inflammatory 
responses, form a mucus layer through production of mucin and produce 
antimicrobial peptides such as β- defensins (Vernier et al. 2015). An example 
would be the recent discovery of mucosal associated invariant T cells around bile 
ducts, which have been shown to upregulate CD40 ligand, IL-12 and IL-18 when 
exposed to E.Coli (Jeffery et al. 2015). 
 
1.3.6 Mechanisms	of	bile	salt	resistance	
As mentioned previously bile acids have bacteriostatic and bactericidal properties. 
However, enteric bacteria have adapted to live in these adverse conditions and 
several pathogenic bacteria including Listeria monocytogenes, Esherichia coli and 
Bacillus cereus are able to invade the gallbladder (Merritt and Donaldson, 2009). 
Therefore it is clear that bacteria have evolved to become resistant to bile salts.  
Several of these mechanisms for resistance occur at a gene level. In the presence 
of bile salts Escherichia coli and Salmonella upregulate genes that protect against 
oxidative stress (Merritt and Donaldson, 2009), allow cells to replicate in the 
presence of DNA damage (Foster, 2007) and repair bile salt induced DNA damage 
through mismatch repair and base-excision repair (Prieto et al., 2006; Cano et al., 
2002). In the presence of bile salts Salmonella and Bacillus cereus upregulate a 
group of genes that are also known to confer multi-drug resistance as well as 
transcribing efflux pumps on the cell membrane to expel bile salts (Prouty et al., 
2004).  
Bacterial spores have a greater resistance to bile salts and therefore endospore 
formation may be mechanism by which bacteria are able to cause enteric infection. 
(Kristoffersen et al., 2007) 
Perhaps the predominant mechanism of bile salt resistance however is through 
induction of bile salt hydrolase (BSH) and 7α dehydroxylase. Bile salt hydrolase is 
found in several bacterial species found in the human intestine including 
Bifidobacteria, Clostridium, Listeria and Lactobacillus (Jarocki et al., 2014). 7α 
dehydroxylase has been found throughout the Clostridium genus (Wells et al., 
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2000).  BSH deconjugates primary bile acids to produce unconjugated bile salts. 
This then allows further metabolism through 7α dehydroxylase to produce 
secondary and tertiary bile acids (Joyce et al., 2014). BSH are thought to facilitate 
incorporation of cholesterol into bacterial membranes thereby increasing the 
tensile stress of the membranes. It is also hypothesised that deconjugation may 
be a means of detoxification of bile salts, although this is currently debated (Begley 
et al., 2005). In addition to aiding resistance deconjugation is thought to confer a 
nutritional benefit to bacteria through provision of carbon, nitrogen and energy 
sources (Begley et al., 2005). The 7α dehydroxylation pathway is a means through 
which bacteria can acquire energy, with bile acids acting as electron acceptors. 
This production of secondary bile acids may also serve to eliminate bacteria 
sensitive to these compounds (Ridlon et al., 2006). 
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1.4 Aims	and	Objectives	of	the	Study	
The aim of this study was to undertake a microbiological assessment of the human 
biliary tract as this is pertinent in health and disease. The objectives within this 
were: 
• To assess whether bile isolated from the normal biliary tract is truly sterile 
• To see if there is a difference in microbial biodiversity between bile isolated 
from diseased gallbladders/biliary tracts containing gallstones, and normal 
gallbladders/biliary tracts 
• To assess whether bacteria isolated from the biliary tract have bile resistant 
properties 
• To investigate changes in microbial biodiversity between PBC and PSC 
when compared to healthy controls 
• To see if treatment and stage of liver disease has an impact on faecal 
microbiota 
• To assess the metabolic activity of the gut microbiota in PBC and PSC 
1.5 Hypothesis	
The human biliary tract is not sterile but has a diverse microbiota, which may play 
a role in the development of liver and biliary disease and that there is a progressive 
dysbiosis in patients with PSC and PBC 
1.6 	 Novelty	
There is emerging evidence that bacteria have a role to play in biliary and liver 
diseases and liver disease. However, studies to date have only examined patients 
with diseased biliary tracts. To my knowledge this is the first study looking to 
characterize the biliary microbiota in normal human bile and compare multiple sites 
within the biliary tree.  
Although dysbiosis has been shown in cirrhosis, at the time of the study no 
publications had looked specifically at primary biliary cholangitis, although a study 
has been published in GUT recently (Tang et al,. 2017). I intend to examine 
changes in microbiota depending on stage of disease of primary biliary cirrhosis 
and cholangitis and compare this to healthy controls. 
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If it can be proven that there is a “normal” bililary microbiota this may lead to further 
studies examining what role these bacteria play in the development of disease and 
whether manipulation of the microbiota may lead to new treatment modalities. 
	
1.7 Ethics	
 
All aspects of this study received ethical approval initially by a Sub – Committee of 
the Faculty of Medicine and Health Sciences Research Ethics Committee, 
University of East Anglia. 
The same body granted subsequent ethical approval for inclusion of patients 
undergoing bowel cancer screening colonoscopy at the Norfolk and Norwich 
University Hospital 
Subsequent ethical approval was granted by the Research and Development 
Department, Cambridge University Hospitals NHS Foundation Trust to allow 
recruitment of patients and collections of biliary samples from Addenbrookes 
Hospital, Cambridge.  
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2 Composition	of	the	biliary	microbiota	
2.1 Introduction	
Conventional wisdom dictates that human bile is sterile. However, until recently it 
has been difficult to analyze human bile in any detail due to difficulty in obtaining 
normal human bile from healthy biliary systems and then providing a specific 
culturing environment to isolate bacteria. Many bacteria require specific conditions 
and media in order to grow and so most remained unculturable.  
However, surgical techniques have improved so that minimally invasive 
procedures done as a day case have now replaced major open cases. As such 
several procedures can now be done laparoscopically in a single surgical session, 
increasing the possibility of obtaining biliary samples. Surgical techniques have 
also advanced so that procedures, such as liver resections for colorectal cancer 
metastases, are now possible. These techniques are summarized in Figure 2-1. 
Newer surgical techniques mean that we are now able to obtain ‘sterile’ biliary 
samples, which was not previously possible.  
The difficulty in obtaining biliary samples is summarized below. In our study, we 
have attempted to obtain “normal” bile through sampling normal gallbladders 
removed at the time of hepatic resection for liver tumours, and sampling the 
common bile duct at the time of laparoscopic cholecystectomy. In order to sample 
bile as normal as possible patients were selected who had biliary colic but normal 
liver function tests, negative cholangiograms at the time of surgery, and no 
prescribed antibiotics. 
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Figure 2-1 Difficulties in obtaining “sterile” biliary samples. Blue lines represent previous attempts to 
characterize the biliary microbiota and the associated issues. Red lines represent sampling methods for this 
study. ERCP = Endoscopic Retrograde Cholangiopancreatogram, GB = Gallbladder, CBD = Common bile duct. 
The advent of Next Generation Sequencing (NGS) has revolutionized our ability to 
sequence a genome, improving accuracy, speed, cost and reducing manpower. 
As a result, we are now able to sequence large amounts of DNA at rapid speed. 
To put this into context the first human genome was sequenced by the Human 
Genome Project, and took 10 years at a cost of $3 billion. Today NGS can 
sequence a single human genome within a day for a cost of several hundred 
dollars. The result of this technological revolution means that we now have a much 
greater understanding of the structure of the human microbiome, and new 
discoveries are being made on an almost daily basis. 
Initially the samples were sent for 454 pyrosequencing; a technique first launched 
by 454 life sciences in 2005.  DNA is fragmented and generic adaptors are added 
to the ends of sequences, which are then annealed to beads. The fragments are 
then amplified by PCR prior to the beads being separated into wells. Thus, each 
well will contain a single bead covered in many copies of a single stranded PCR 
amplicon. The wells are then flooded with one of the four nucleotides (cytosine, 
thymine, adenine, guanine). If the nucleotide is complementing, it is bound to the 
DNA strand. If the nucleotide is repeated then more will be added. Each time a 
nucleotide is added a light signal is released, the more nucleotides that are added 
the stronger the light signal. The process is repeated for each nucleotide, and 
graphs are generated for each nucleotide wash. A computer reading the graph can 
then generate the DNA sequence. 
The	Problem	
Cholecystectomy;	
Gallstones	
Inﬂamma2on	
An2bio2c	use	
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Dilated	biliary	
system	
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CBD	sampling:	
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47 
 
 
Figure 2-2 The 16S rRNA amplicon is fragmented and immobilized on beads (each bead crucially 
only attaches one DNA fragment). Fragments are amplified by emulsion PCR in an oil–aqueous 
solution and applied to a picotiter plate. The wells are then flooded with one of the 4 nucleotides. 
When a nucleotide base is incorporated a chemoluminescent signal is released, which is read into 
a pyrogram. Analysis of the pyrogram can, therefore, show the order of the nucleotide bases and 
thus phylogenetic identification is possible by comparison to databases. Adapted from Fraher et al 
2012. 
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During the course of this project it became possible to have sequences analysed 
using the Illumina platform. Illumina is different to 454 in that it uses shorter 
fragments, which are annealed to a slide using adapters. PCR is performed to 
amplify each read, and the amplicons are then separated into single strands to be 
sequenced. The slide is flooded with fluorescently labeled nucleotides containing 
a terminator so only one base can be added at a time. An image is taken of the 
entire slide, the terminators are then removed and the process repeated. A 
computer reading the images then generates the DNA sequence.  
 
Figure 2-3 Outline of Illumina genome analyzer sequencing process. (1) Adaptors are annealed to 
the ends of sequence fragments. (2) Fragments bind to primer-loaded flow cell and bridge PCR 
reactions amplify each bound fragment to produce clusters of fragments. (3) During each 
sequencing cycle, one fluorophore attached nucleotide is added to the growing strands. Laser 
excites the fluorophores in all the fragments that are being sequenced and an optic scanner 
collects the signals from each fragment cluster. Then the sequencing terminator is removed and 
the next sequencing cycle starts. Adapted from Kulski J 2016 
 
 
 
 
 
49 
 
The advantages of Illumina over 454 sequencing are summarized below (Luo et 
al., 2012). 
 
Table 2-1 Advantages of Illumina sequencing over 454 
It is due to this that Roche decided to abandon 454 sequencing technology in 2014 
and phased out the technique over the following 18 months. 
The aim of this study was to culture bacteria under aerobic and anaerobic 
conditions on several generalized media. However, given that many bacteria were 
likely to require specific growth conditions in order to grow, samples were also sent 
for NGS in order to identify those bacteria that were unculturable. The quantity of 
bile salts in each sample was also analysed to see if this had an affect on the 
growth of bacteria.  
  
Advantages 
More complete genes recovered due to higher sequencing error rates with 
454 
Greater depth of coverage 
Cheaper in terms of sequences generated per pound 
Ability to upgrade and improve sequencing method unlike 454 
Improving technology means larger reads now possible – a previous 
weakness of illumina 
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2.2 Methods	and	Materials	
 
2.2.1 Patient	selection	
 
Patients undergoing liver resection, pancreatic surgery or laparoscopic 
cholecystectomy at the Norfolk and Norwich University hospital or Addenbrookes 
hospital were screened. Patients were excluded if they had active infection or had 
received antibiotics within the previous 6 weeks, if they had biliary intervention 
(ERCP, sphincterotomy, biliary stents), if they had previous biliary surgery, or had 
any episodes of jaundice preceding surgery. 
 
2.2.2 Sample	collection	
 
Samples were collected at the time of surgery.  For common bile duct samples, the 
CBD was identified and dissected. The gallbladder was clamped and either a 
sterile needle was inserted (during open resection surgery) or the duct was partially 
cut and a sterile catheter inserted. Up to 5 ml of bile was aspirated prior to 
cholangiography.  
Bile samples were obtained from the gallbladder via a sterile needle once it had 
been removed from the patient. 
Samples were then transferred to a sterile bijou which had been placed for 24 
hours in an anaerobic cabinet.  
 
2.2.3 Metataxonomics	
2.2.3.1 Media	Preparation	
 
To try and maximize the potential growth of bacteria, 4 broad spectrum non-
selective media were chosen. Luria - Bertani (LB) broth is rich in nutrients, and the 
most widely used medium for the growth of bacteria. De Man, Rogosa and Sharpe 
(MRS) agar is a medium developed primarily for the cultivation of lactobacilli, but 
is also used for the cultivation of the whole group of lactic acid bacteria. It is not 
selective at pH values greater than 5.7 (Progress in Industrial Microbiology Vol 37, 
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2003). Brain Heart Infusion (BHI) medium is a general-purpose nutrient medium 
recommended for the cultivation and isolation of a variety of micro-organisms. 
Blood agar is an enriched, bacterial growth medium that encourages the growth of 
fastidious organisms such as Streptococci and Haemophilus.  The composition of 
each medium in shown in Table 2-2. 
Table 2-2 Compositions of bacterial culture media. 
 
2.2.3.2 Sample	preparation	
 
Samples were transferred to the anaerobic cabinet and 100ul of each sample was 
diluted in 900ul of PBS to create dilutions of 1/10, 1/100, 1/000. 100ul of samples 
were then transferred to BHI, MRS and blood plates as well as liquid BHI. The 
diluted samples were then also plated aerobically on LB, BHI, MRS and blood 
plates. 100ul of undiluted samples was inoculated into liquid BHI. Plates were then 
left to grow at 37°C, and examined for growth at 24 and 48 hours. The remaining 
bile samples were then frozen at -20°C for use in metagenomics studies later. 
Media Composition in 1L H2O pH 
LB agar Tryptone 10g, Yeast extract 5g, Sodium Chloride 
10g 
Agar 15g 
 
MRS agar Peptone 10g, “Lab-Lemco” powder 8g, Yeast 
extract 4g, Glucose 20g, Sorbitol mono-oleate 
1ml, Di-potassium hydrogen phosphate 2g, 
Sodium acetate H2O 5g, Tri-ammonium citrate 2g, 
Magnesium Sulphate 7H2) 0.2g, Magnesium 
Sulphate 4H2) 0.05g, Agar 15g 
6.2 +/- 0.2 
BHI agar Brain infusion solids 12.5g, Beef heart infusion 
solids 5g, Proteose peptone 10g, Sodium Chloride 
5g, Glucose 2g, Disodium Phosphate 2.5g, Agar 
15g  
7.4 +/- 0.2 
Blood agar Pancreatic Digest of Casein 14.5g, Peptic digest 
of Soybean Meal 5g, Sodium Chloride 5g, 
Koenzyme Enrichments 1.5ml, Horse Blood 50ml, 
Agar 14g 
7.4 +/- 0.2 
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Colonies were sampled using a sterile loop and replated to ensure a single colony 
was isolated. Total numbers of colonies were counted to calculate the number of 
colonies per ml of bile. 
A single colony was inoculated into 10ml of BHI and incubated at 37°C for 24 hours. 
500ul of sample was then transferred to a 2ml eppendorf containing 500ul 40% 
glycerol and frozen on dry ice before being transferred to -80°C freezer to form 
frozen glycerol stocks for future use in bile resistance studies. 
2.2.3.3 Colony	PCR	
 
Colonies were identified through single colony 16S rDNA PCR.  A single colony 
was isolated using a sterile toothpick and transferred to 10ul of ultra-pure H2O. This 
was then boiled at 95°C for 5 minutes, and 1ul was used as a template for PCR. 
The PCR reaction was set up as follows; 
Table 2-3 PCR amplification materials 
The following universal primers were used as per Baker et al (2004) 
AMP_F 5’ GAG AGT TTG ATY CTG GCT CAG 
AMP_R 5’ AAG GAG GTG ATC CAR CCG CA 
 
 
 
 
Reagent Quantity (ul) 
Template 1 
5x buffer 10 
dNTP 0.4 
Primer Forward 1 
Primer Reverse 1 
goTaq 0.25 
upH20 36.35 
Total 50 
53 
 
Table 2-4 PCR programme used for amplification of 16S rRNA genes 
In order to confirm DNA amplification gel electrophoresis was performed. A 1% 
(w/v) agarose gel was prepared by dissolving 5g agarose powder in 500ml of 
0.5mM Tris/borate/ethylenediaminetetraacetic acid (TBE) buffer. This was then 
microwaved (800 watts) for 2 minutes at full power to aid dissolution. The 1% (w/v) 
agarose solution was added to an electrophoresis gel tray in a horizontal gel 
electrophoresis system with a 6mm toothed comb fitted and allowed to cool and 
set. TBE (5 mM) was added to cover the gel. 2 ul Bioline Hyperladder I was added 
to the outer well to act as a molecular weight marker. 2 ul of DNA and 0.5 ul 10x 
loading dye were added to the remaining wells. The gel was run at 100 volts until 
the samples had migrated to the end of the gel, as indicated by the loading dye. 
The gels were submerged in ethidium bromide solution for 30 minutes and rinsed 
with water. DNA fragments were visualised and photographed using the 
AlphaImager HP system under ultra-violet transillumination. 
Once DNA amplification was confirmed, the amplicons were purified, using 
QIAquick PCR purification Kit. 5 volumes of buffer PB with pH indicator were added 
to 1 volume of the PCR sample. If the sample was not yellow 10ul of 3M sodium 
acetate was added to ensure pH was <7.5.  The sample was then transferred to a 
binding column and centrifuged at 17 900 xg for 60 seconds. The column was then 
washed twice with Buffer PE before DNA was eluted with 10mM Tris-HCl pH 8.5. 
15ul of purified DNA and 2 ul of either forward or reverse primer (10pmol) was 
added to a barcode and sent to Eurofins for 16s rDNA Identification of isolate 
bacteria 
The quality of the 16S rDNA sequencing data was initially assessed using  FinchTV 
software (Geospiza, Inc.). The paired samples which had been sequenced with the 
AmpF and AmpR primers were assembled into a single contig using SeqMan 
Stage Number Number of 
Cycles 
Temperature (°C) Time 
Stage 1 1 95 2 minutes 
Stage 2 25 95 30 seconds 
55 30 seconds 
72 90 seconds 
Stage 3 1 72 5 minutes 
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(DNASTAR, Inc). This was then checked for errors or mismatches through 
FinchTV. 
These quality-checked sequences were then uploaded to The Ribosomal 
Database Project Sequence Matching tool (Cole et al., 2014).  The search options 
enabled were both type and non-type strains, uncultured and isolate sources, near 
full length sequences and good quality sequences. The identification of the 
bacterial isolates was determined on the basis of the highest similarity (S_ab) 
score. An S_ab score of greater than 95% allows for classification in the same 
genus, below that in the same family. S_ab scores of less than 90% were 
discarded. 
 
2.2.4 Metagenomics	
2.2.4.1 Bacterial	DNA	extraction	
 
Bacterial DNA was extracted using an optimized protocol for the Invitrogen 
Purelink Genomic DNA Mini Kit adapted from the manufacturers protocol for Gram 
Positive Bacterial Cell Lysate, with the addition of mutanolysin to promote bacterial 
wall breakdown. 
Following the addition of 96% ethanol to Genomic Wash Buffer 1 and 2. Lysozyme 
digestion buffer was prepared using the following recipe:  
Table 2-5 Composition of Lysozyme Digestion Buffer 
Fresh lysozyme was added to obtain a final lysozyme concentration of 20 mg/mL 
followed by mutanolysin at a final concentration of 10 U/mL. 
Samples were thawed and 1 ml of bile was centrifuged for 15 minutes at 4°C at 14 
500 xg. The supernatant was then removed and the pellet was re-suspended in 
180ul of lysozyme digestion buffer. The solution was then mixed through vortexing 
before being left to incubate in a water bath set at 37°C for 30 minutes.  
Ingredient Volume (in 10ml Ultra Pure H2O) Final Concentration  
Tris-HCl 1M 250 ul 25 mM  
EDTA 0.5M 50 ul 2.5 mM  
Triton X-100 100 ul 1%  
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20 ul of Proteinase K (a protease widely used for digestion of proteins in nucleic 
acid preparations) was added to the solution. The solution was vortexed before 
adding 200ul PureLink Genomic Lysis/Binding Buffer. The solution was then left to 
incubate in a water bath set at 55°C for 30 minutes.  
200 ul of 96% Ethanol was added to the lysate and mixed through vortexing for 5 
seconds to yield a homogenous solution. 
The lysate was added to a PureLink Spin Column in a collection tube and 
centrifuged at 10 000 xg for one minute at room temperature.  The collection tube 
was discarded and the spin column placed in a clean PureLink Collection Tube. 
The sample was “washed” with 500ul Wash Buffer 1 and centrifuged at 10 000 xg 
at room temperature for 1 minute. The spin column was placed in a fresh collection 
tube and 500 ul of Wash Buffer 2 was added before being centrifuged at 14 000 
xg for 3 minutes at room temperature. 
The spin column was placed in a sterile 1.5 mL Eppendorf tube, and 25 ul of 
PureLink Genomic Elution Buffer was added to the column to obtain a maximal 
yield of DNA. The sample was left to incubate at room temperature for 3 minutes 
before being centrifuged at 14 000 xg for 1 minute. The process was then repeated 
with another clean 1.5mL Eppendorf in order to recover more DNA. The sample 
was centrifuged at 14 000 xg for 90 seconds. 
The concentration of DNA in the samples was assessed via Nanodrop and the 
purified DNA stored at -20C. 
 
2.2.4.2 Amplification	and	sequencing	of	16S	rDNA	gene	regions	
 
PCR amplification of the 16S rRNA gene V4 region, and subsequent DNA 
sequencing for the first 12 samples was performed at the Animal Health and 
Veterinary Laboratories Agency (AHVLA) using 454 pyrosequencing as per Ellis et 
al (2013) 
Subsequently all samples were sent to the Earlham Institute (Norwich), and DNA 
sequencing was performed using the MiSeq Illumina platform as per standard 
protocols (Caporaso et al., 2012) 
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2.2.4.3 Bioinformatic	analysis	of	16S	rDNA	data	
 
Samples were analysed using Quantitative Insights Into Microbial Ecology 
(QIIME), an open-source bioinformatics pipeline for performing microbiome 
analysis from raw DNA sequencing data.  QIIME enables the analysis of raw data 
generated by sequencing platforms to generate graphics and statistics including 
taxonomic assignment, relative number of operational taxonomic units (OTUs) and 
diversity analyses. 
2.2.5 Bile	salt	analysis	
2.2.5.1 Sample	preparation	
 
1 ml of bile was centrifuged at 14 000 xg for 15 minutes at 4°C. The supernatant 
was then removed and transferred to fresh tubes that were frozen at -20°C prior to 
analysis. 
2.2.5.2 Bile	salt	Mass-Spectrometry	analysis	
 
The composition of bile acids in the gallbladder and common bile duct samples 
were determined using HPLC-MS/MS by Mr Mark Philo at the Quadram Institute.  
In summary, a 20 ul aliquot was taken and diluted with 5% methanol – 1000x for 
bile duct samples and 10 000 xg for gallbladder samples. Reference standards of 
Lithocholic acid (LCA), cholic acid (CA), chenodeoxycholic acid (CDCA), 
deoxycholic acid (DCA), Glycochenodeoxycholic acid (GCDCA) were added at a 
final concentration of 0.5ug/ml. All samples were analysed according to the 
instrument and standard preparation conditions for the determination of bile acids 
in mouse liver and digestive tract (see Standard operating procedure in Appendix 
2) 
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2.3 Results	
2.3.1 Optimization	of	DNA	extraction	
 
Several attempts at DNA extraction were made before an optimal protocol was 
achieved. Initially bacterial DNA was extracted using a modified protocol for 
FastDNA Spin Kit for soil (MPBio). Wu et al (2013) had used lysis through 
mechanical disruption in order to extract DNA from gallbladder bile samples and 
this was incorporated into the method used for this study. 
Initially 200ul of bile obtained from the gallbladder was defrosted and used as had 
been described in previous studies. (Wu et al., 2013). Unfortunately, this did not 
yield a measurable concentration of DNA, therefore 1ml was used and centrifuged 
for 15 min at 14 500 xg at 4°C.  The supernatant was removed and the pellet re-
suspended in 978ul of sodium phosphate buffer. 122ul of MT buffer was added 
and vortexed for 20 seconds. This solution was then left to stand for 1 hour at 4°C 
(being vortexed every 15 mins). 
Approximately 1ml of sample was then transferred into a Lysing Matrix E Tube.  
Samples were then lysed using the FastPrep Instrument for 1 minute at 6.5m/s. 
This was repeated 3 times allowing the samples to cool for 5 mins in between 
steps. 
The lysing matrix tubes were then centrifuged at 14 900 xg for 1 minute. The 
supernatant was then transferred to a clean Eppendorf tube. 250ul of PPS reagent 
was added and the solution hand mixed 10 times. 
The solution was then recentrifuged at 14 900 xg for 5 minutes to pellet precipitate. 
The supernatant was then transferred to a sterile 15ml tube. 1 ml of Binding Matrix 
Suspension was added to the supernatant and inverted by hand for 2 minutes. The 
tubes were then left to stand for 3 minutes to allow the settling of the silica matrix.  
1 ml of the supernatant was then removed and discarded. The binding matrix was 
re-suspended in the remaining supernatant. 
600ul of mixture was then transferred to into a “spin filter tube” and centrifuged for 
1 minute. The matrix was washed 3 times with 500 ul SEWS-M and centrifuged at 
14 500 xg for 1 minute with each wash.  Following the final wash, the tubes were 
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centrifuged a final time at 14, 500 xg for 2 minutes to “dry” the matrix of residual 
SEWS-M wash solution. 
The spin filters were then left to air dry for 2 mins before 50 ul of DNase/Pyrogen 
Free water was added. The tube was then centrifuged for 1 minute in order to elute 
DNA.  
Good results were obtained from initial samples from the gallbladder, although 
DNA yields were low in comparison to faecal samples. However, when repeat DNA 
extraction was performed on samples isolated from undiseased bile ducts, the 
levels of DNA were often unrecordable by using Nanodrop (<0.1 mg/ul) 
A review of the literature revealed that another group had extracted DNA from 400 
ul noncentrifuged bile, obtained during ERCP for common bile duct stones, using 
the Invitrogen Purelink Genomic DNA Mini Kit, following manufactor’s blood DNA 
extraction protocol. (Shen et al., 2015) 
However, this technique resulted in similar yields of DNA as obtained from 
mechanical disruption.  A hybrid method was performed whereby DNA extraction 
was attempted through enzymatic lysis followed by mechanical disruption, with 
repeated poor yields. Given that the majority of bacteria previously isolated were 
gram positive, a method was adapted based on lysozyme digestion which is 
described in section 2.2.4.1. 
2.3.2 Demographics	
 
In total 55 patients were screened for this study. One patient did not consent for 
the study. 12 patients were immediately excluded due to antibiotics or previous 
biliary intervention, a further 3 patients were excluded at the time of surgery due to 
a decision not to proceed with resection due to cancer progression and six patients 
were then excluded as the gallbladder was perforated at the time of removal, or 
biliary samples were unable to be aspirated from the common bile ducts.  
Therefore 39 samples of bile were obtained from 33 patients (6 patients had 
samples taken from the gallbladder and common bile duct).  
The bile samples were taken from 4 groups depending on pathology; “normal” 
Gallbladder (GB), “normal” Common bile duct (CBD), “diseased” Gallbladder, and 
“diseased” Common bile duct. The pathological reason for surgery are summarized 
in Table 3-6, whilst the demographics of patients are summarized in Table 3-7. 
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Due to the relatively small numbers in the “normal’ GB and “diseased” CBD groups, 
there is a discrepancy in average age. However, the age range across all groups 
is comparable. The male: female ratio, smoking history, and alcohol consumption 
is similar across the groups.  
Table 2-6 Bile sample source, surgical procedure and underlying pathology 
 
Table 2-7 Demographics of patients 
2.3.3 Metataxonomics	
2.3.3.1 Bacterial	growth	
In total 149 discrete morphological colonies were identified from the 39 samples. 
On obtaining 16S PCR sequencing results some of these were identified as the 
Bile Sample 
Source 
“Normal” GB 
n = 5 
“Normal” CBD 
n = 15 
“Diseased” GB 
n = 14 
“Diseased” CBD 
n = 4 
Surgical 
procedure 
Liver Resection 
n = 5 
Cholecystectomy 
n = 13 
Cholecystectomy 
n = 15 
ERCP 
Reason for 
surgery 
• Colorectal 
Cancer 
metastases 
x 3 
• Adenoma 
• Carcinoid 
• Gallstones x 13 • Gallstones x 13 
• Chronic 
Cholecystitis 
• Polyp 
• Biliary stricture in 
PSC 
Surgical 
procedure 
 Pancreatic resection 
n = 2 
 Cholecystectomy 
n = 3 
Reason for 
surgery 
 • Duodenal 
adenoma 
• Pancreatic 
cancer 
 • Gallstones with 
positive 
cholangiogram   x 
3 
Patient Group “Normal” 
GB 
N = 5 
“Normal” 
CBD 
N = 15 
“Diseased” 
GB 
N = 15 
“Diseased” 
CBD 
N = 4 
Average Age (Years) 67 (37 – 
82) 
61 (33 – 
76) 
59 (37 – 82) 47 (25 – 78) 
Male:Female ratio 
(%) 
40:60 53:47 47:53 25:75 
Smoking % 
(Current, Never, Ex) 
20:60:20 7:80:13 13:80:7 0:100:0 
Alcohol % 
(YES, NO) 
20:80 40:60 40:60 0:100 
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same species grown from the same sample but on different media. Therefore, a 
total of 115 bacterial taxa were grown from 39 samples and of these, 91 were 
identified with an S_ab score of greater than 95%. Of the remaining 24 samples, 
nine of these the microbial growth spread to form a lawn on the agar plates, and 
on microscopic examination had hyphae in keeping with them being fungi.  The 
remaining 14 samples had S_ab scores of less than 80% despite repeat PCR and 
sequencing. 
The bacteria isolated from the different samples are summarized in Table 3-8. The 
frequencies of bacteria by diseased group are summarized in Table 3-9. 
The most abundant genera isolated were Staphylococcus, Bacillus, Micrococcus 
and Enterococcus. Samples taken from “diseased” gallbladders tended to contain 
more bacteria (in terms of colonies per ml) than was found in “diseased” common 
bile ducts. In total 79 different species were isolated across all patient groups; 24 
different species (excluding unidentified bacteria) were isolated from “diseased” 
gallbladders, 16 from “normal” common bile ducts, 10 from “diseased” common 
bile ducts and 6 from “normal” gallbladder. Increased bacterial growth was 
observed on BHI and blood media agar. All anaerobic bacteria were subsequently 
found to grow in aerobic conditions making them facultative anaerobes. This also 
suggests that any obligate anaerobes present may have not survived the transfer 
from the surgical theatre to the anaerobic cabinet. 
Interestingly, several samples, particularly those taken from the common bile duct, 
contained more bacterial colonies per ml when plated at 1/1000 dilution compared 
to 1/10, thereby suggesting an inhibitory effect on replication by a substance within 
the sample. This also means that it was not possible to accurately calculate the 
numbers of colonies per ml. 
Samples 2 (Hepatic resection for carcinoid) and 10 (Primary Sclerosing Cholangitis 
and ERCP) grew motile bacteria; Paenibacillus lactis and Pseudomonas 
aeroginosa. Several other colonies were also present on these samples, but these 
were unable to be isolated and identified due to contamination from the motile 
bacteria. For sample 25 (gallbladder and common bile duct) a similar problem was 
encountered however repeat plating eventually yielded single morphological 
colonies. 
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Table 2-8 (Over 5 pages) Morphology of colonies, bacteria Identified by 16S rRNA gene sequencing, similarity 
scores (s_ab) of extracted sequences and origin of sample. Colonies marked “unidentifed” either had 
sequences reads that were too short or s_ab scores that were below 0.80. GB = gallstones, CBD = common bile 
duct, PSC = primary sclerosing cholangitis. ERCP = endoscopic retrograde cholangiopancreatogram 
Sample 
ID Morphology Sequencing result 
s_ab 
score Origin 
RW1 
Small white 
circular 
Intrasporangiacae 
janibacter 0.974 
Gallstones and 
cholecystitis 
RW2 
Small white 
circular Janibacter sanguinis  0.981 
Gallstones and 
cholecystitis 
RW3 Swarming Paenibacillus lactis 0.963 Carcinoid 
RW4 
Large white 
circular Enterococcus faecium 0.983 
Gallstones and 
cholecystitis 
RW6 
Small 
translucent Unidentified  N/A 
Gallstones and 
cholecystitis 
RW7 
Small 
translucent Citrobacter freundii 0.989 
Gallstones and 
cholecystitis 
RW8 
Small cream 
circular Enterobacter asburiae 0.94 
Gallstones and 
cholecystitis 
RW10 
Small white 
circular Enterococcus faecalis 0.986 
Gallstones and 
cholecystitis 
RW11 Swarming Proteus 0.896 
Gallstones and 
cholecystitis 
RW15 Large yellow Unidentified N/A 
Gallstones and 
cholecystitis 
RW16 
Large 
irregular 
Clostridium 
perfringens 0.983 
Gallstones and 
cholecystitis 
RW17 
Large 
irregular Cronobacter sakazakii 0.98 
Gallstones and 
cholecystitis 
RW19 
Small white 
circular Enterococcus faecalis 1 
Gallstones and 
cholecystitis 
RW20 
Large white 
circular Bacillus Circulans 0.987 Benign lesion 
RW23 
Cream 
circular 
Staphylococcus 
epidermidis 1 
gallstones and 
cholecystitis 
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RW24 
Large white 
circular 
Stapylococcus 
hominis 0.979 
gallstones and 
cholecystitis 
RW25 
Yellow 
circular Micrococcus luteus 0.986 
gallstones and 
cholecystitis 
RW26 Swarming Paenibacillus lactis 0.965 
Gallstones and 
cholecystitis 
RW27 
Cream 
circular 
Staphylococcus 
epidermidis 0.994 
Colorectal cancer 
metastases 
RW29 White circular 
Staphylococcus 
hominis 1 PSC and stents 
RW30 
Small white 
circular Enterococcus faecium 0.983 PSC and stents 
RW31 Mucoid 
Pseudomonas 
aeroginosa 0.998 PSC and stents 
RW33 
Yellow 
circular Micrococcus luteus 0.973 
Colorectal cancer 
metastases 
RW34 
white semi 
opaque 
Staphylococcus 
epidermidis 1 
Colorectal cancer 
metastases 
RW35 White circular Staphyloccis hominis 0.976 
Chronic 
cholecystitis 
RW36 White fan-like 
Corynebacterium 
aurimucosum 0.967 
Chronic 
cholecystitis 
RW39 
Large white 
circular 
Staphylococcus 
epidermidis 0.994 
Chronic 
cholecystitis 
RW40 
Yellow 
circular 
Staphylococcus 
pasteuri 0.997 
Colorectal cancer 
metastases 
RW41 White circular Bacillus licheniformis 1 
Colorectal cancer 
metastases 
RW43 
Off white 
circular  
Staphylococcus 
pasteuri 0.994 
Duodenal 
adenoma 
RW44 White circular 
Staphylococcus 
epidermidis 0.994 
Duodenal 
adenoma 
RW45A White circular 
Staphylococcus 
epidermidis 0.996 Pancreatic Cancer 
RW45B 
Yellow 
circular Acinetobacter iwoffi 0.987 Pancreatic Cancer 
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RW45C 
Yellow 
circular Micrococcus luteus 0.996 Pancreatic Cancer 
RW46L White small 
Staphylococcus 
epidermidis 0.994 Pancreatic Cancer 
RW46S Yellow large 
Staphylococcus 
pasteuri 0.997 Pancreatic Cancer 
RW48 White circular 
Staphylococcus 
hominis 1 
Gallstones CBD 
sample  
RW50 
Yellow 
circular 
Staphylococcus 
capitis 0.996 
Gallstones CBD 
sample 
RW51 
Cream 
circular Bacillis firmis 1 
Gallstones CBD 
distal stone 
RW52 
Yellow 
circular Micrococcus luteus 0.988 
Gallstones CBD 
distal stone 
RW53 Small white 
Lactobacillus 
rhamnosus 1 
Gallstones CBD 
sample 
RW54 Large white 
Staphylococcus 
hominis 0.999 
Gallstones CBD 
sample 
RW56 White circular Unidentified  N/A 
Gallstones CBD 
sample 
RW57 
Yellow 
circular Unidentified  N/A 
Gallstones CBD 
sample 
RW58 Small white Unidentified  N/A 
Gallstones CBD 
sample 
RW59 Large yellow Micrococcus luteus 1 
Gallstones CBD 
sample 
RW60 Large white 
Staphylococcus 
epidermidis 1 Pancreatitis CBD  
RW62 White circular 
Staphylococcus 
lugdunesis 1 Pancreatitis CBD  
RW63 
Yellow 
circular 
Micrococcus 
yunnanensis 1 Pancreatitis CBD  
RW65 White ragged Unidentified N/A  Pancreatitis CBD  
RW66 White circular 
Staphylococcus 
hominis 1 Pancreatitis CBD  
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RW68 White circular 
Staphylococcus 
hominis 0.991 
GS CBD distal 
stone 
RW69 
Yellow 
circular Micrococcus luteus 0.984 
GS CBD distal 
stone 
RW70 White circular 
Staphylococcus 
epidermidis 0.999 
GS CBD distal 
stone 
RW71 
Yellow 
ragged Massila sp 0.984 
GS CBD distal 
stone 
RW73 Large white Klebsiella varicola  0.981 
Gallstones - Prev 
ERCP 
RW74 Small white Enterococcus faecalis 0.991 
Gallstones - Prev 
ERCP 
RW83 
Yellow 
circular Micrococcus luteus 0.996 
Gallstones GB  
sample 
RW84 White circular 
Staphylococcus 
epidermidis 0.989 
Gallstones GB  
sample 
RW85 
Small yellow 
circular 
Staphylococcus 
aureus 0.995 
Gallstones GB 
sample 
RW86 
Yellow 
Circular 
Staphylococcus 
epidermidis 1 
Gallstones CBD 
sample 
RW87 
Yellow 
circular 
Staphylococcus 
aureus 0.995 
Gallstones CBD 
sample 
RW88 
Large white 
circular Bacillus cereus 1 Gallstones 
RW89 Grey ragged Unidentified N/A Gallstones 
RW92 
Small off 
white 
Streptococcus 
sanguinis 1 Gallstones 
RW93 
Large white 
circular 
Staphylococcus 
hominis 1 Gallstones 
RW94 White circular Unidentified N/A  
Gallstones CBD 
sample 
RW95 Grey circular 
Staphylococcus 
epidermidis 0.999 
Gallstones CBD 
sample 
RW96 White circular Variovorax 1 
Gallstones CBD 
sample 
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RW99 White circular 
Staphylococcus 
capitis 1 
Gallstones CBD 
sample 
RW100 Grey circular 
Staphylococcus 
hominis 1 
Gallstones GB 
sample 
RW101 White fan-like Acintomyces viscosus 1 
Gallstones GB 
sample 
RW102 
Yellow 
circular Neisseria perflava 0.996 
Gallstones GB 
sample 
RW103 
White 
Spreading Unidentified N/A  
Gallstones GB 
sample 
RW104 White circular Bacillus subtilis 1 
Gallstones GB 
sample 
RW105 
Yellow 
circular Micrococcus luteus 1 
Gallstones GB 
sample 
RW106 Bright White 
Staphylococcus 
haemolyticus 1 
Gallstones GB 
sample 
RW107 Spreading Unidentified N/A  
Gallstones CBD 
sample 
RW108 Spreading Unidentified N/A  
Gallstones CBD 
sample 
RW109 Spreading Unidentified N/A  
Gallstones GB 
sample 
RW110 
Off white 
circular Bacillus cereus 1  
Gallstones GB 
sample 
RW111 Spreading Unidentified N/A  
Gallstones GB 
sample 
RW112 Spreading Unidentified N/A  
Gallstones GB 
sample 
RW113 Spreading Unidentified N/A  
Gallstones GB 
sample 
RW114 Spreading Unidentified N/A  
Gallstones CBD 
sample 
RW115 
Yellow small 
circular 
Corynebacterium 
imitans 0.926 
Gallstones CBD 
sample 
RW116 White circular Enterococcus faecalis 0.995 
Gallstones CBD 
sample 
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RW117 White coned Rothi dentocariosa 0.995 
Ductal Stones   
CBD 
RW118 White circular 
Staphylococcus 
epidermidis 0.992 
Ductal Stones   
CBD 
RW119 
Small white 
circular Bacillus cereus 1 
Ductal Stones   
CBD 
RW120 White circular 
Staphylococcus 
epidermidis 1 Gallstones GB  
RW121 
Yellow small 
circular 
Corynebacterium 
imitans 0.968 Gallstones GB  
RW122 
Yellow 
circular Bacillus subtilis 0.97 Gallstones GB  
RW123 
Yellow 
circular Micrococcus luteus 1 
Ductal Stones   
GB 
RW124 Dot like 
Staphylococcus 
salivarius 1 
Ductal Stones   
GB 
RW125 
Yellow 
circular Bacillus cereus 0.998 
Ductal Stones   
GB 
RW126 White circular 
Staphylococcus 
pasteuri 0.989 
Ductal Stones   
GB 
RW127 White circular  
Staphylococcus 
epidermidis 1 
Ductal Stones   
GB 
RW128 White circular 
Staphylococcus 
salivarius 0.947 Gallstones GB 
RW129 
Ragged 
White 
Staphylococcus 
hominis 0.988 Gallstones GB 
RW130 Haemolysis Bacillus cereus 0.87 
Ductal Stones 
CBD 
RW131 Haemolysis Bacillus cereus 1 Gallstones GB 
RW132  White ragged Unidentified N/A  Gallstones CBD  
RW133 
 White 
circular Unidentified N/A  
Gallstones CBD 
sample 
RW134  White ragged Unidentified N/A  
Gallstones GB 
sample 
RW135 
 White 
circular Unidentified N/A  
Gallstones GB 
sample 
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Table 2-9 Frequency of bacteria per disease cohort  
RW136 
 Yellow 
circular Micrococcus luteus 1 Gallbladder polyp 
RW139 
 White 
circular 
Staphylococcus 
epidermidis 1 Gallbladder polyp 
RW140  Spreading Unidentified N/A  Gallbladder polyp 
RW141 
 White 
circular 
Staphylococcus 
hominis 0.986 Gallbladder polyp 
RW142 
 White 
circular Unidentified N/A  Gallbladder polyp 
RW144 
 White 
circular 
Staphylococcus 
caprae 1 
Gallstones CBD 
sample 
RW146 
 Yellow 
circular 
Corynebacterium 
imitans 0.832 
Gallstones CBD 
sample 
RW147 
 White with 
haemolysis 
Staphylococcus 
haemolyticus 1 
Gallstones CBD 
sample 
RW149 
 White 
circular Unidentified N/A 
Gallstones CBD 
sample 
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2.3.4 Metagenomics	
 
In total, all 39 samples underwent DNA extraction using the optimised protocol for 
DNA extraction from blood, and were sent for amplification of the V4 and V5 
variable regions of the 16S rRNA gene before being sequenced commercially via 
the MiSeq illumina platform. Prior to this, 12 gallbladder samples had been sent for 
sequencing via the 454-pyrosequencing platform using the modified protocol for 
soil. Enough extracted DNA remained from 4 of these samples to send for 
sequencing via Illumina, thereby allowing direct comparison of the 2 techniques. 
Table 3-10 summarizes the total sequence reads per sample. 
  
Table 2-10 Sequence reads per sample comparing Illumina versus 454 pyrosequencing methods. Numbers 
were generated using Qiime 
Illumina generated sequence reads roughly 10 times the number of sequence 
reads per sample than that of 454 pyrosequencing. 
The quantity of DNA was generally low when quantified using nanodrop (ranging 
between 1.3 and 150.1 ng/ul) when compared to faecal samples where the 
concentrations were > 250 ng/ul (See Appendix for full list of results). Each sample 
had the DNA extracted twice using the revised method. In total, 27/39 samples 
passed quality control and were sent for library reconstruction; 5 “normal” GB 
samples, 5 “diseased” GB samples, 14 “normal’ CBD samples and 3 “diseased” 
CBD samples. The biggest fail rate was within the “diseased” GB cohort (10/15 
samples), but this may reflect the fact these samples had been stored for the 
Sample Number of reads per sample 
Illumina 454 pyrosequencing 
Gallstones + cholecystitis 
Gallbladder bile 
92568 9288 
Hepatic adenoma 
Gallbladder bile 
93181 3236 
Carcinoid 
Gallbladder Bile 
72172 12140 
Colorectal Cancer 
Metastases  
Gallbladder Bile 
173776 1881 
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longest period of time at -20°C, or had had been thawed the largest number of 
times which may have led to DNA degradation. 
The sequences were analysed using the QIIME pipeline (section 3.4.2). This 
produced 3317945 high quality reads, with an average of 114412 ± 51247 reads 
per sample. 
 
2.3.4.1 Biliary	microbiota	composition	
 
The relative abundance of each bacterial genus within each sample is represented 
as a percentage proportion of each operational taxonomic unit within the 
microbiota as a whole. The samples have been separated into disease groups 
(Figure 2-2).  In order to assess the differences in microbiota across groups the 
mean proportion of each phylum and genus was calculated and displayed as a pie 
chart (Figures 2-3 and 2-4). 
In total six phyla were isolated across the disease groups. The most abundant 
phylum in all the disease groups was Proteobacteria, followed by Firmicutes. There 
was a marked shift in Proteobacteria: Firmicutes ratio in the “diseased” gallbladder 
group compared to the other 3 groups. Bacteroidetes only made up a small 
proportion of all bacterial taxa. 
 
Figure 2-4 Pie charts showing relative abundance of each bacterial phylum by disease group. Each colour 
represents a bacterial phylum weighted by percentage contribution to overall bacterial population. 
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In total, 34 genera had percentage proportions greater than 0.5%. The most 
diverse microbiota was found in the “Normal” GB group, with diversity observed 
within both CBD groups. 
Across the 4 groups the most abundant genus was Pseudomonas, representing 
34% (SD 25%), 69% (SD 21%), 34% (SD 39%), 51% (SD 33%) for “normal” GB, 
“normal” CBD, “diseased GB” and “diseased” CBD, respectively. The standard 
deviations suggest that there is variability throughout the samples in regards to 
proportion of Pseudomonas. However, when looking at the samples individually 
Pseudomonas is the most prevalent genus in 13/14 “Normal” CBD samples, 4/5 
“Normal” GB samples, 2/5 “Diseased” GB, and 3/3 “Diseased” CBD. 
There is an emerging dysbiosis in the “Diseased” GB group with the relative 
abundance of Enterococcus being greater than the other groups (21% ± 33%) 
although this does not reach statistical significance (p = 0.3). This is reflected in 
2/5 samples having Enterococcus as the predominant genus. 
The variation in Pseudomonas is generally related to changes in one other genus 
within the group. In the “Diseased” GB group Pseudomonas is decreased due to 
an increased abundance of Enterococcus. Within the CBD groups there is an 
increase in relative abundance of Pseudomonas due to a lack of Klebsiella when 
compared to the GB groups. 
When the standard deviations of the remaining genera are compared, there is a 
stability of the proportions of these bacteria across the samples, with 20 of the 
genera having SD < 1%. The most prevalent genera after Pseudomonas, 
Enterococcus and Klebsiella are Janthinobacterium (5.3% SD 2%), Ruminococcus 
from the Ruminococcaceae family (3% SD 1.5%) and Acinetobacter (2% SD 
0.8%). The “Other” bacteria (those that were present at less than 0.5% of total 
operational taxonomic units) made up 5.1% ± 2.7%. 
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Figure 2-5  Column charts representing bacterial taxa identified in each sample through sequencing of 16S 
rDNA. Each colour represents a bacterial taxon weighted by % contribution to total bacterial population. Only 
bacterial taxa contributing >0.5% are shown. Those taxa representing <0.5% are shown as “other”  
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Figure 2-6 Pie charts showing relative abundance of each bacterial taxa by disease group. Each colour 
represents a bacterial taxon weighted by percentage contribution to overall bacterial population. Only those 
taxa that were present at >0.5% of the total bacterial population are shown individually. Bacteria that 
contributed <0.5% are shown as “Other”  
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To see if there were any similarities in the microbiota composition between 
samples principal coordinates analysis (PCoA) was performed on the sequencing 
data. When CBD and GB samples were compared, the GB samples were disparate 
suggesting variation within microbiota. However, in regards to the CBD samples 
there was definite clustering with 13/17 samples being in close proximity, thereby 
suggesting a core microbiome.  
Figure 2-7: PCoA analysis comparing CBD samples (red dots) and GB samples (blue dots). The central cluster is 
expanded to reveal close clustering of CBD samples. Figure generated using QIIME 1.9.0 pipeline. 
2.3.5 Bile	Salt	composition	
	
The concentrations of bile salts in each of the 39 samples were analyzed. The 
average concentration of each of the bile salts by disease sample is summarized 
in table 2-11.  
As expected, the concentrations of bile salts from the gallbladder were 
approximately 10 times that of the common bile duct.  However, as the standard 
deviations for each demonstrate, there is great variation between samples. The 
concentration of the primary bile salt cholic acid is comparable between “normal” 
and “diseased” common bile ducts. There is an apparent difference between 
“normal” and “diseased” gallbladders (446 ug/ml vs 149 ul/ml). However, due to 
the standard deviations no statistical difference was observed between the groups 
(P – value of 0.75443 using unpaired 2 –tailed t test). 
Deoxycholic acid, a secondary bile acid, had the most stable concentrations across 
the four groups. As secondary bile salts are solely produced through bacterial 
deconjugation and 7α dehydroxylation, this suggests that there may be a core 
Principle Component Analysis
Key:	
=	CBD	microbiota	
=	GB	microbiota	
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microbiome in human bile, and bile salt concentration does not affect the 
microbiota composition. 
 
Table 2-11 Average concentrations of each of the bile acids (ug/ml) by disease group. Samples in orange reflect 
primary bile acid. The sample in blue reflect secondary bile acid. Samples in yellow reflect conjugated bile salts. 
To explore this further the average proportion of each bile salt was calculated and 
expressed as a percentage of the total bile salt number for each disease group. 
This was then compared to the average sequence reads per sample produced 
through NGS (Figure 2.6). There is a significantly higher proportion of taurocholic 
acid and taurochenodeoxycholic acid in the “diseased” common bile duct (P –value 
0.015) and a non-significant lower proportion of deoxycholic acid and a 
corresponding rise in glycine conjugated derivatives (glycodeoxycholic acid, 
glycohyodeoxycholic acid, and glycoursodeoxycholic acid) in the “normal” 
gallbladder group (P – value 0.6). However, this does not correlate with the 
average number of sequence reads per sample, which have no statistical 
difference between groups. 
This is clearer when the samples are compared individually (Figure 2.7). There is 
no correlation between the proportion of primary, secondary and conjugated bile 
salts in these samples and the number of sequence reads per sample, meaning a 
larger number of secondary bile salts in a sample is not as a result of a higher 
number of bacteria. 
Although there is a large proportion of Pseudomonas in “normal” common bile duct 
samples (section 3.5.3) there does not appear to be any difference in the bile acid 
composition of these samples when compared to the other groups. 
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 Figure 2-8 Average reads per sample by disease group and proportion of bile salts per disease group 
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Figure 2-9 Sequence reads per sample (A) as sequenced by Illumina with corresponding proportions of bile 
salts per sample, with each colour corresponding to individual bile salts. 
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2.4 Discussion	
2.4.1 Bile	is	not	sterile	
 
This study is the first to have shown that normal human bile is not sterile and 
contains a core microbiome. Culture-dependent techniques isolated a wide range 
of bacteria, and in patients with known gallstones or diseased biliary tract, the most 
frequently isolated bacteria tended to be pathogenic, due to an association with 
sepsis. Klebsiella, Enterococcus, Enterobacter, Pseudomonas, Proteus, and 
Citrobacter are all associated with biliary sepsis in humans (Csendes et al., 1996; 
Brook, 1989).  One study reported that the bacterial family Enterobacteriaceae 
were responsible for 35% of all positive cultures taken at ERCP in symptomatic 
patients (Hakalehto et al., 2010). Therefore, the types of bacteria isolated in this 
study are in agreement with what would be expected to be found within a diseased 
and inflamed gallbladder.  
However, there were also many bacteria from other families isolated both from the 
“diseased” and ‘normal” systems, which are not typical of biliary sepsis. These 
included Staphylococcus, Micrococcus, and Bacillus. It could be argued that the 
Staphylococci, especially Staphylococcus epidermidis, may represent 
contaminants. However, Staphylococci are frequently isolated from diseased bile 
ducts and gallbladders in humans (Hakalehto et al., 2010; Brook, 1989). In a recent 
study using pigs it was found that Staphylococcus epidermidis was one of the most 
common isolates from bile samples (Jimenez et al., 2014). The study team also 
swabbed the outer walls of the gallbladders to ensure this was not a contaminant, 
and these were found to be sterile.  
When culture-dependent techniques and the results from the next generation 
sequencing were compared it became clear that 63% of the bacteria present in bile 
were not culturable. There are several explanations for this. Firstly, the study used 
general non-selective media and more bacteria may have been isolated if we had 
used additional selective media. Secondly, no obligate anaerobes were cultured, 
which may be due to the time taken to transfer samples from the surgical theatre 
to the anaerobic cabinet. Thirdly, it may be possible that some of the bacteria 
isolated could inhibit the growth of other bacteria within the same sample. It has 
been shown that bile resistant Staphylococcus aureus has an inhibitory effect on 
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coliform growth when in mixed cultures, whilst also encouraging its own growth 
(Hotterbeekx, A et al. 2017). 
The metataxonomic data from NGS suggests that there is a diverse microbiota 
within normal human bile. Although the amount of DNA extracted was low when 
compared with faecal studies, the actual range and diversity of the bacteria isolated 
suggests that there is a complex microbiome within the biliary system. This is 
particularly evident in the “normal” gallbladder group, whereas in the “diseased” 
gallbladder group there is an emerging dysbiosis for Enterococcus and Klebsiella. 
This suggests that in the diseased gallbladder, pathogenic bacteria colonize the 
bile at the expense of the core microbiota. This may be due to colonization of 
gallstones, or impaired flow of bile and cholestasis. The loss of 10/15 “diseased” 
samples due to failure of quality controls may have had an impact on these results. 
However only 1/5 “diseased” samples showed the same high diversity as the 
“normal” samples and 2/5 samples had a large predominance of Enterococcus 
suggesting that bigger numbers may have made this finding more significant. 
Equally the small numbers of samples in the “normal” gallbladder group were still 
representative given that 4/5 samples showed consistent microbial diversity. 
No data has been published from next generation sequencing regarding bacteria 
at the genus level for the biliary microbiota. However, there is some information on 
phyla level break down. In a study looking at bile in gallstone disease in an Eastern 
population, Wu et al (2013) measured 2493 counts per sample, whereas Jimenez 
et al (2014) measured roughly 48 000 counts per sample when examining pig bile 
from normal gallbladders. In comparison, this study measured an average of 136 
973 counts per sample. These other studies used 454 pyrosequencing whereas 
this study used the Illumina platform, which is known to generate considerably 
more reads than 454. When comparing phyla level data, the most predominant 
phyla were Proteobacteria, Firmicutes, Bacteroidetes, and Actinobacteria, which 
corresponds with the findings in these other two studies. However, both these 
studies found Firmicutes to be the predominant phyla, followed by Proteobacteria 
in pig bile, and Bacteroidetes in the human study. When the “diseased” gallbladder 
group is taken in isolation there is a change in the Firmicutes: Proteobacteria ratio, 
which more closely resembles the findings of Wu et al.  
Pseudomonas was the predominant genus throughout all 4 groups as well as in 
21/27 samples. Pseudomonas is a gram-negative bacillus, and is a common 
inhabitant of soil and surfaces in aqueous environments (Gellatly and Hancock, 
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2013). It is an opportunistic pathogen that can cause serious health issues in 
immunocompromised patients (Hassett et al., 2010; Bicking et al., 2017), and is a 
leading cause of morbidity and mortality in patients with serious underlying medical 
conditions. It is also known to colonise the human host, for example it is the leading 
cause of chronic lung infection in patients with cystic fibrosis (Langton Hewer and 
Smyth, 2017). One of the reasons for this is that it has multiple adaptive 
mechanisms that make it resistant to antibiotics, drugs, and host defense 
mechanisms (Gellatly and Hancock, 2013). As such, it is reasonable to assume 
that it would be able to survive in the harsh environment of the human biliary tree. 
Pseudomonas is known to cause biliary sepsis, and in a recent study looking at 
gallbladder bile in Colombian patients with gallstones, Pseudomonas was the most 
prevalent isolate (Arteta et al., 2017).  
The bile salt concentration between samples showed great variability. The 
concentrations of primary bile salts were low, with greater numbers of conjugated 
bile salts. Given that most conjugation occurs within the liver, this is to be expected. 
The concentrations of secondary bile salts were relatively stable across the 
samples and disease groups. The fact that secondary bile salts were identified 
within the bile suggests that bacteria are producing these prior to excretion into the 
bowel. The stability across the samples also suggests that there may be a core 
microbiota which can utilize the primary bile salts. There did not seem to be a 
correlation between bile salt composition and relative proportions of bacterial taxa. 
Therefore, the core microbiota is able to survive within the bile ducts regardless of 
the composition of bile salts. 
The difficulty with analysis of the microbiota of human bile is that it is not possible 
to obtain normal bile samples. The same accusation could be leveled at this study 
as even the normal groups were undergoing surgery for gallstones, 
pancreatic/ampullary disease or hepatic tumours. This has been minimized by 
selecting biliary colic patients who had not had previous biliary intervention, had 
never had abnormal liver function tests, had not required treatment for biliary 
sepsis, and had normal bile duct imaging both pre- and peri-operatively. However, 
it is possible that in the gallstone patients, small stones may have passed through 
the common bile duct causing disruption to the Sphincter of Oddi, and therefore 
allowing for reflux of small bowel bacteria. Equally, in the duodenal adenoma and 
pancreatic cancer patients there was the possibility of impaired biliary flow and 
subclinical cholestasis. Therefore, perhaps the most important group with regards 
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to sterility is the “normal” gallbladder group. Although these patients were having 
surgery for liver tumours, this should not affect the microbial composition of the 
gallbladder and biliary tract as there was no evidence of biliary disease or 
inflammation, and the background liver in these patients was normal. These 
samples therefore give a good approximation of the core biliary microbiome.  
Regarding the bowel, there is a certain level of disagreement over whether the 
faeces, mucus layer, or mucosal biopsies are best for sampling and assessing the 
colonic microbiota, and the same question could be asked with regards to the 
biliary tract. However, in studies to date, fluorescent in situ hybridization of the 
diseased bile ducts has failed to identify any viable bacteria (Swidsinski et al., 
2005). Equally, examination of the mucus layer of gallbladders in pigs revealed 
bacterial counts much lower than those found in bile (Jimenez et al., 2014).  
The amount of bacterial DNA from biliary samples was much lower than other sites, 
such as faeces, as reflected by a third of samples failing quality control prior to 
NGS due to insufficient DNA. In order to try and optimize this, multiple methods 
were used and adapted. The method that yielded the highest results relied upon 
enzymatic lysis and lysozyme digestion. It is not clear if this is the best method for 
extracting small concentrations of DNA from samples. Optimisation of this method 
meant that biliary samples needed to be repeatedly thawed, which could have 
caused denaturation of DNA and therefore a reduction in yields.  
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3 Functional	assessment	of	the	biliary	microbiota	
3.1 Introduction	
 
Bacteria resident in the human intestine have a dualistic relationship with bile 
acids. Whereas bile acids are toxic to a large proportion of pathogenic and some 
commensal bacteria, many have evolved to survive in the harsh environment of 
the gastrointestinal tract and even convey a beneficial effect through the production 
of secondary bile acids, and the removal of toxic bile acid compounds (see section 
1.3.6) 
In the previous chapter 115 different bacterial species were isolated. These 
bacteria would have had to adapt to be able to survive in a bile salt rich 
environment. This poses the question as to their mechanism of survival. Are these 
bacteria able to upregulate pathways that protect them from oxidative stress and 
DNA damage?  Are they able to upregulate efflux pumps to expel bile acids from 
the cell? Or do they transform bile salts and use then as energy sources through 
the bile salt hydrolase and 7σ dehydroxylase. 
The aim of this chapter is to assess if the bacteria isolated from the human biliary 
tract are able to survive and replicate in the presence of bile salts at physiologically 
relevant concentrations, and therefore establish if they have the potential to be 
commensal or simply transient residents. Bile salt hydrolase (BSH) activity of the 
most bile salt resistant bacteria will also be assessed. 
3.2 Materials	and	Methods	
3.2.1 Bile	Salt	Resilience/Resistance	
3.2.1.1 Growth	curve	analysis	by	optical	density	
 
To assess the isolated bacteria’s ability to survive in the presence of bile salts, 
stored bacterial glycerol stocks were thawed and 10 ul inoculated into 10ml BHI 
and allowed to grow overnight at 37°C. 
Initial testing resulted in poor growth curves at even low concentrations of bile salts 
from many of the bacteria tested. It was hypothesized that during storage the 
bacteria may have downregulated non-essen
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inoculated into media containing Bile Salts (Oxoid No 3) at a concentration of 
0.15% (w/v). 
Bile salts were added to BHI media at the following concentrations; 0.2%, 0.5%, 
1%, 3%, 5% and 10% (w/v) 
Bile salts were dissolved in 100ml of BHI placed in a 37°C water bath before the 
media solution was steri-filtered into a new sterile bottle. These concentrations 
were used to mimic concentrations of bile salts seen in the gallbladder (up to 10%), 
common bile duct (up to 1%), and small bowel (0.5%). 
Two 100 well Bioscreen plates were set up with triplicate samples of each 
concentration plus a 0% control (250ul in each well), and 10ul of the fresh inoculate 
was added to the appropriate wells. Growth curves were generated over a 48-hour 
period using a Bioscreen C microbiological growth monitoring system, which 
incubates, agitates and measures turbidity of up to 200 wells simultaneously. 
Following the initial bile salt studies, it became clear that a large proportion of 
bacteria were unable to replicate in the presence of bile salts. As many of these 
bacteria were isolated from the common bile duct where concentrations of bile salts 
are only up to 1% it was possible that the bacteria isolated may be able to survive 
transiently without proliferating, or were growing at a rate not detectable by the 
Bioscreen C machine. Thus, an experiment was designed to measure colony 
forming units to determine growth at 24 and 48 hours and therefore assess whether 
bacteria were able to survive when exposed to low dose bile salts at a 
concentration similar to that of the common bile duct. 
 
3.2.1.2 Determination	of	growth	by	colony	forming	units	
 
Glycerol stocks were defrosted and 10 ul of each were added to separate 10ml 
aliquots of BHI broth. The cultures were left to incubate aerobically at 37°C 
overnight. 
BHI agar plates were prepared and air-dried in the sterile laminar flow hood. Liquid 
BHI media containing 0.15% Bile salts was prepared as described previously.  
The BHI cultures were removed from the incubator and serial dilutions were 
performed by taking 100 ul of culture and adding to 900 ul of BHI broth. This was 
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repeated to obtain dilutions to 10-8, and 20ul of the appropriate dilutions were 
spotted in triplicate on the BHI agar plate. After drying, plates were left to incubate 
aerobically at 37°C overnight. 
10 ul of each inoculated media was then added to 990 ul of BHI media containing 
0.15% bile salts and placed in the incubator for 24 hours to assess growth following 
exposure to bile salts. After 24 hours samples underwent the same process for 
dilutions as above, before being incubated for a further 24 hours at 37°C. 
The plates were examined for bacterial growth.  The dilution upon which separate 
colonies could be identified and counted (between 10 and 30) per spot was used. 
The number of colonies were averaged and a total colony count per ml in the initial 
sample was calculated. This was repeated for baseline, 24 hours post exposure to 
bile salts, and 48 hours post exposure to bile salts. 
 
3.2.1.3 Bile	Salt	Hydrolase	activity	
 
A protocol adapted from Sedlackova et al. (Sedlackova, 2015) was used to assess 
if any of the most resilient bacteria survived following exposure to bile salts was 
due to bile salt hydrolase activity. 
Glycerol stocks of the 10 most resilient bacteria were thawed, 10ul were added to 
10ml PBS and 20ul was spread on BHI plates and incubated aerobically overnight 
at 37 ° C.  
Soft agar plates (0.75%) containing calcium chloride 0.375 g/L and 0.5% Bile salts 
no. 3 were prepared. 
Colonies were stabbed into the agar and left to incubate at 37°C for 72 hours. If 
BSH was active then a halo would develop around the puncture site, and results 
were assessed by measuring the diameter of the halos. These measurements 
were repeated 3 times. 
To see if exposure to bile salts had an effect on inducing BSH activity following 
glycerol storage, the same bacteria were also incubated in BHI liquid media 
containing 0.15% bile salts (made as previously described in 3.3.2.1) overnight 
before being plated on BHI plates. The same protocol was then followed.  
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3.3 Results	
3.3.1 Bile	salt	resistance	studies	
 
To observe if bacteria cultured from bile could survive physiological concentrations 
of bile salts, resistance studies were performed. 132 colonies from 39 samples 
were tested in triplicate. In total 20/132 colonies grew in media containing >5% bile 
salts. Of these several colonies were identified as the same genus grown from the 
same bile sample but on different media. Therefore, 12 distinct bacterial species 
were found to be resistant to high concentrations of bile salts. Growth curves for 
these bacteria are shown in figure 2-1. 
Nine of the bacteria were isolated from four diseased gallbladders. The other three 
were isolated from three different common bile ducts, two normal and one at time 
of ERCP. 
11/12 of the bacteria grew best in media containing no bile or 0.2% bile salts and 
then growth was progressively inhibited as bile salts concentrations increased. 
Citrobacter freundi grew best in low concentrations of bile salts but negative effects 
were observed at higher doses. The minimal inhibitory concentration for most of 
the bacteria was between 5 and 10%. 
As bile salt concentration increased, growth was delayed by up to 24 hours. This 
suggests that the bacteria were able to induce pathways which had been 
downregulated during storage, to enable survival and proliferation in media 
containing bile salts. 
Citrobacter, Klebsiella, Enterobacter, Proteus, Cronobacter and one of the 
unidentified bacteria had an initial rapid growth phase in low dose bile salts (0.2 to 
0.5%) before growth slowed and then plateaued suggesting that they were using 
bile salts as a source of energy until the reserves became depleted within the 
media. 
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Figure 3-1 Growth curves for 12 bacterial species in increasing concentrations of bile salts. Growth curves were 
generated through optical density 260xnm using the Bioscreen C microbiological growth monitoring system. 
Each bacterial species was grown in triplicate and the growth curves generated represent an average of the 3 
experiments 
 
 
En
te
ro
co
cc
us
	fa
ec
al
is
En
te
ro
co
cc
us
	fa
ec
iu
m
Co
ry
ne
ba
ct
er
iu
m
	im
ita
ns
En
te
ro
ba
ct
er
	a
sb
ur
ia
e
Ci
tr
ob
ac
te
rf
re
un
di
87 
 
3.3.2 Bile	salt	tolerance	studies	
 
As many of the bacteria were unable to proliferate in media containing bile salts, it 
was decided to examine whether bacteria were able to survive in media containing 
0.2% modified bile salts, which is physiologically relevant for the common bile duct 
(Coleman et al., 1979). 
116 bacterial colonies were analysed, with the number of colony forming unit (CFU) 
per ml calculated at baseline, 24 hours and 48 hours. 
Three patterns (A, B and C) were observed and are summarised in figures 3-2, 3-
3 and 3-4. 
Pattern A demonstrated an initial decrease in the number of colonies within the 
first 24 hours, and colony numbers remained stable between 24 and 48 hours. 
Bacteria that followed this pattern were generally isolated from the gallbladder and 
are highlighted in table 3-2. 
Pattern B showed a progressive decline in the number of colonies from baseline 
to 48 hours. Although this suggests that bile salts may restrict the growth of these 
bacteria the bacteria were still viable at 48 hours. These bacteria were 
predominantly isolated from the common bile duct, which suggests that they may 
only be present transiently. These bacteria are highlighted in table 3-3. 
Pattern C showed an initial fall in numbers at 24 hours with subsequent recovery 
and proliferation between 24 and 48 hours thereby suggesting the induction of 
pathways to allow survival following exposure to bile salts. These bacteria were 
isolated from the common bile duct and gallbladder. The bacteria that followed this 
pattern are highlighted in table 3-4. 
Staphylococcus epidermidis, Staphylococcus pasteuri and Micrococcus luteus 
displayed more than one of the patterns observed. This suggests that there is 
variability within species with regards to bile salt tolerance, depending on the 
source of the bacteria and pathways, which were up or down regulated in storage. 
88 
 
 
Figure 3-2: Pattern A; CFU per ml of four bacterial species following exposure to 0.2%  (W/v) bile salts. Numbers 
of colonies are presented as log10. Pre-bile salts = Bacteria inoculated in BHI media for 24 hours and then 
plated on BHI agar and counted. Post-bile salts = Bacteria subsequently inoculated into BHI media containing 
0.2% bile salts before being plated on normal BHI and counted. Each experiment was performed in triplicate 
and the average shown. 
 
Table 3-1; Identity of bacteria that show initial decline in growth following exposure to bile salts with 
subsequent stability of numbers between 24-48 hours. GB = gallbladder, CBD = common bile duct. 
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Paenibacillus lactis Normal GB 
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Figure 3-3 Pattern B; CFU per ml of four bacterial species following exposure to 0.2%  (W/v) bile salts. Numbers 
of colonies are presented as log10. Pre-bile salts = Bacteria inoculated in BHI media for 24 hours and then 
plated on BHI agar and counted. Post-bile salts = Bacteria subsequently inoculated into BHI media containing 
0.2% bile salts before being plated on normal BHI and counted. Each experiment was performed in triplicate 
and the average shown. 
 
Table 3-2 Identity of bacteria that show progressive decline in growth over 48 hours following exposure to bile 
salts. GB = gallbladder, CBD = common bile duct 
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Figure 3-4 Pattern C; CFU per ml of four bacterial species following exposure to 0.2%  (W/v) bile salts. Numbers 
of colonies are presented as log10. Pre-bile salts = Bacteria inoculated in BHI media for 24 hours and then 
plated on BHI agar and counted. Post-bile salts = Bacteria subsequently inoculated into BHI media containing 
0.2% bile salts before being plated on normal BHI and counted. Each experiment was performed in triplicate 
and the average shown. 
 
Table 3-3 Identity of bacteria that show initial decline following exposure to bile salts with subsequent 
proliferation between 24 and 48 hours. GB = gallbladder, CBD = common bile duct 
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91 
 
3.3.3 Bile	Salt	Hydrolase	(BSH)	activity	
 
The bacteria that exhibited growth in higher concentrations of bile salts to identify 
whether they demonstrated bile salt hydrolase activity were stabbed into soft agar 
plates containing bile salts and calcium chloride. A white precipitate will form 
around the inoculation point of the bacteria that have bile salt hydrolase activity   
The bacteria were recovered from glycerols and inoculated in bacterial growth 
media with and without bile salts to see if exposure to bile salts prior to inoculation 
resulted in an increase in BSH activity. 
 
 
Figure 3-5 Growth plates assessing Bile Salt 
Hydrolase activity. Colonies were stabbed into soft agar containing bile salts and calcium chloride. If bacteria 
have bile salt hydrolase activity then a white precipitate is seen after 72 hours. Red boxed samples represent 
negative controls. 
 
Seven bacteria that had shown strong resistance to bile salts were chosen for 
testing, along with three controls that had not been able to proliferate during the 
bile resistance experiments. The results are shown in figure 3-5 with the 
measurements and bacteria tested shown in table 3-4. 
Unidentified bacteria (132), Proteus sp (11) and Cronobacter sakazakii (17) had 
the strongest reaction to the bile salts producing the largest halos. As expected, 
the negative controls had no bile salt hydrolase activity. Pseudomonas aeroginosa 
(31) and Enterococcus faecalis (19) also showed no bile salt hydrolase activity, 
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thereby suggesting that these bacteria have other mechanisms by which they are 
resistant to bile. There appeared to be no difference in the size of halo following 
pre-exposure to bile salts (table 3-4). 
Table 3-4 Average maximum diameter (mm) of halos measured after 72 hours’ incubation of bacteria grown 
in either normal media or media containing 0.2% bile salts. Bacteria highlighted in blue did not proliferate in 
bile salts on previous testing and therefore acted as controls. 
 
3.4 Discussion	
 
Bile salts provide an important barrier to bacterial infection through their 
bactericidal properties. However, bacteria have adapted and evolved so that many 
are bile salt resistant and able to survive in even the high concentrations of bile 
salts in the gallbladder. In this chapter, the bacteria that had been isolated from the 
human biliary tree were grown in similar concentrations of bile salts as seen in the 
common bile duct (0.2-1%) and gallbladder (6-9%) (Coleman et al., 1979). Only 12 
of the bacteria that were tested were able to proliferate in concentrations of >5%. 
Bacteria Sample 
Number  
Average halo 
diameter (no bile 
salts) (mm) 
Average halo diameter 
(bile salts) (mm) 
Citrobacter freundii 7 8 9 
Proteus sp 11 18 18 
Cronobacter 
sakazakii 
17 16 15 
Enterococcus 
faecalis 
19 1 1 
Staphylococcus 
hominis 
24 0 NA 
Pseudomonas 
aeroginosa 
31 0 NA 
Staphylococcus 
pasteuri 
43 <1 1 
Staphylococcus 
epidermidis 
44 <1 1 
Corynebacterium 
imitans 
115 2 2 
Unidentified bacteria 132 25 25 
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Unsurprisingly, the majority of these bacteria were isolated from gallbladders. 
Enterobacter, Enterococcus, Citrobacter, Klebsiella, Proteus, Pseudomonas, 
Cronobacter sakazakii, and Corynebacterium are all known to be resistant to bile 
salts (Nami et al., 2015; Hakalehto et al. 2010; Fakruddin et al., 2014). These 
bacteria are also known to be pathogenic, with most identified as causes of biliary 
sepsis (Hakalehto et al., 2010). Cronobacter sakazakii is a food-borne pathogen 
that has been linked with outbreaks of food poisoning, especially in infants due to 
contaminated infant formula milk, (Ueda, 2017; Endersen et al., 2017) however 
asymptomatic carriage has been reported. 
Staphylococcus species are known to have bile resistant properties. However, in 
this study, none of the isolated Staphylococci were able to grow in concentrations 
of >5% bile salts. However, many of the isolated species were able to survive and 
even proliferate in low concentrations of bile salts (0-0.2%). This suggests that the 
isolated species were able to induce pathways to allow survival in the presence of 
bile salts. It is also possible that whilst in storage as glycerols these bacteria 
downregulated non-essential pathways in order to conserve energy. Therefore, if 
exposed to higher concentrations of bile salts for a longer period of time, there may 
have been increased growth beyond the end of the bile salt resistance studies. All 
of the samples were exposed to bile salts when removed from storage so an 
experimental control measuring growth over 48 hours without bile salts to see if 
bacteria had adapted to bile salts for survival would be beneficial. 
Although only a few bacteria could actively proliferate in >5% bile salts, the majority 
of them were able to survive for at least 48 hours in concentrations of bile salts 
similar to those expected in the common bile duct. All of the bacteria that were 
isolated from the biliary tract are also known to inhabit the normal human intestine. 
It is therefore possible that those bacteria which were not proliferating in the 
presence of bile salts were there transiently following reflux from the small 
intestine. It has previously been shown that patients with confirmed sphincter of 
Oddi laxity and cholangiolithiasis have a more varied biliary microbiota than those 
that do not when bile was sampled at ERCP (Liang et al., 2016). Also, previous 
biliary intervention has been shown to be a risk factor for positive biliary cultures 
at the time of endoscopic sampling (Rupp et al., 2016). Therefore, it is possible 
that bacteria refluxing from the small intestine may have an influence on the core 
biliary microbiome, which equally may have a role to play in the development of 
biliary disease. Little is known about the duodenal microbiota but it is unlikely that 
variations in small bowel microbiota between patients influenced the results given 
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that patients with risk factors for small bowel bacterial overgrowth and coeliac 
disease were excluded. 
Seven of the most resilient bacteria were assessed for BSH activity, and four of 
these formed clear halos, suggesting that they exhibited strong BSH activity. 
Citrobacter had a smaller halo when compared to Proteus and Cronobacter. 
However, when the growth curves were examined, Citrobacter had a stronger 
response in low concentrations of bile salts than the other bacteria, suggesting that 
they were able to utilize bile salts as a source of energy as well as the media 
nutrients. Conversely, three of the bacteria did not show any BSH activity, and 
these tended to grow slower, and with a lower maximum load, than those bacteria 
who were able to utilize BSH. Therefore, they likely have other pathways that 
provided protection against the negative effects of bile salts, which they were able 
to upregulate in order to replicate. Thus, bacteria isolated from the human biliary 
tract have different methods by which they are able to survive, and in some cases, 
proliferate. These adaptations may also have an effect on the host, and therefore 
be a possible mechanism through which biliary disease occurs. 
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4 Assessment	of	faecal	microbiota	in	cholestatic	liver	disease	
4.1 	 Introduction	
Chronic cholestasis refers to impairment of bile formation and flow. If untreated it 
can lead to hepatocyte damage and bile duct destruction through retention of bile 
salts constituents. This in turn can lead to hepatic fibrosis and ultimately cirrhosis 
(de Vries and Beuers, 2017). The two most common chronic cholestatic liver 
diseases are Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis 
(PSC).  
PBC is a chronic, immune mediated, progressive liver disease. It is characterized 
by inflammation of the small and medium sized intrahepatic ducts which then leads 
to fibrosis and eventually cirrhosis. It generally effects middle aged women and 
has an indolent course. Symptoms are non-specific and include pruitis, fatigue and 
in the later stages jaundice and chronic liver failure. As such it is often not 
diagnosed until quite advanced, or coincidentally on blood testing for other causes. 
PSC is characterized by irregularities, stricturing and upstream dilatation 
effectiveness of the intra and extra-hepatic ducts, which like PBC can progress to 
fibrosis and cirrhosis. It effects men more than women and is generally diagnosed 
at an earlier age. Symptoms generally consist of pruitis, abdominal pain, fatigue, 
weight loss and symptoms of biliary sepsis. There is an association between PSC 
and inflammatory bowel disease with a co-existence of around 70%. 
Treatment options for these conditions are limited. Ursodeoxycholic acid (UDCA), 
a secondary bile acid, is the first line treatment for PBC. 40% of patients do not 
respond to UDCA. It is thought to work through stimulating biliary secretion of bile 
acids thereby reducing bile acid cytotoxicity, protecting hepatocytes from bile acid-
induced apoptosis through inhibition of mitochondrial membrane permeability 
transition and protection of cholangiocytes from cytotoxicity of hydrophobic bile 
acids by modulating the composition of mixed phospholipid-rich micelles (Purohit 
and Cappell, 2015). These patients have a worse prognosis in terms of transplant 
free survival. The effectiveness of UDCA in PSC is less clear. Although liver 
biochemistry improves there is no proven benefit in terms of survival (EASL, 2009). 
Recently obeticholic acid, a farcenoid X receptor agonist, has been licensed for 
use in UDCA non-responders for patients with PBC (Nevens et al., 2016). Fibrates, 
for example bezafibrate, have also been shown to improve liver biochemistry and 
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can be used off license (Cheung et al., 2016; Suraweera et al., 2017). No new 
treatments have been shown to be effective in PSC. 
The aetiology of these conditions is unclear. Genetic, auto-immune and 
environmental factors have been implicated and likely predispose an individual to 
development of the conditions, but do not fully explain pathogenesis. There is 
emerging evidence that bacteria may have a role to play in the development of 
these conditions. Molecular mimicry, whereby antibodies in the sera of PBC 
patients that bind to self – peptides also cross-react to conserved bacterial 
proteins, which include Escherichia coli and Lactobacillus delbrueckii. This may 
explain the breakdown of self-tolerance seen in PBC.  The bile of PBC patients 
undergoing liver transplant has been found to contain predominantly Gram-positive 
cocci on 16S RNA analysis, in comparison to Gram-negative bacteria in patients 
with gallstones. However, this study did not identify bacteria in the bile of patients 
without hepatobiliary disease in contrast to this and other studies (see also 
chapters 2 and 3). More indirect evidence includes the association of recurrent 
urinary tract infections with PBC. 
Given that PSC has a close association with IBD, recent research has focussed 
on the gut microbiota and cholestatic liver disease. In PSC, a distinct dysbiosis in 
patients with PSC and ulcerative colitis (UC) has been observed which is separate 
from the dysbiosis seen in UC alone (Sabino et al., 2016; Quraishi et al., 2017). 
Within the last few weeks work has been published suggesting that there is a 
dysbiosis associated with PBC which may be partially reversed with UDCA therapy 
(Tang et al., 2017). 
The aims of this chapter were to confirm whether there is a dysbiosis associated 
with PBC and PSC, to see if any change is related purely to stage of liver disease, 
to compare PSC and PBC microbiota and to see if UDCA therapy has an impact 
on microbiota in these conditions. 
 
 
4.2 		Sample	collection	
 
Performing a search of the Norfolk and Norwich University Hospital patient letter 
database identified patients with primary sclerosing cholangitis and primary biliary 
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cholangitis. The letters were then reviewed and patients were excluded if they were 
on long-term antibiotics including rifaximin, had current decompensated liver 
disease or previous liver transplant. 
Patients were then contacted in writing with a subsequent follow up phone call 
unless they expressed a wish to not be included in the study.  
Exclusion criteria at the time of interview were use of antibiotics within the 
preceding 6 weeks, current or recent use of probiotics, use of laxatives, recent 
diarhoeal illness, current decompensation, and recent variceal bleed. 
Control patients were identified through the bowel cancer screening programme. 
These patients are asymptomatic but have tested positive for faecal occult blood 
on stool testing and therefore are invited for colonoscopy. Patients were consented 
at the pre-assessment clinic. 
Exclusion criteria for controls were recent use of antibiotics or probiotics, recent 
use of laxatives, bowel resection, history of liver disease and recent diarrhoea. 
Samples were collected prior to colonoscopy and bowel cleansing. If subsequently 
positive for bowel cancer on endoscopy then these samples were ommited from 
the study. 
Patients were given a home collection kit for faeces and urine and samples were 
then collected from their homes within 2 hours. Given that patients were recruited 
from the whole of Norfolk this proved to be unsustainable in terms of distance 
traveled and availability to collect samples. Therefore postal kits were 
subsequently provided. 
On arrival at the laboratory faecal samples were then aliquoted into 6 faecal 
collection tubes and stored at -20°C. Urine samples were frozen directly. 
 
4.3 Materials	and	Methods	
4.3.1 DNA	extraction	
 
DNA was extracted using the modified protocol for the FastDNA Spin Kit for Soil 
(MPBio) (Maukonen et al., 2006) 
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0.2 g of frozen faecal sample was weighed and placed into a 10ml sterile test tube. 
978 ul of sodium phosphate buffer and 122 ul of MT buffer was added and vortexed 
for 20 seconds. This solution was then left to stands for 1 hour at 4°C (being 
vortexed every 15 mins). 
Approximately 1ml of sample was then transferred into a Lysing Matrix E Tube.  
Samples were then lysed using the FastPrep Instrument for 1 minute at 6.5m/s. 
This was repeated 3 times allowing the samples to cool for 5 mins in between 
steps. 
The lysing matrix tubes were then centrifuged at 14 900 xg for 1 minute. The 
supernatant was then transferred to a clean Eppendorf tube. 250 ul of PPS reagent 
was added and the solution hand mixed 10 times. 
The solution was then centrifuged at 14 900 xg for 5 mins to pellet precipitate. The 
supernatant was then transferred to a sterile 15ml tube. 1 ml of Binding Matrix 
Suspension was added to the supernatant and inverted by hand for 2 minutes. The 
tubes were then left to stand for 3 minutes to allow the settling of the silica matrix.  
1 ml of the supernatant was then removed and discarded. The binding matrix was 
re-suspended in the remaining supernatant. 
600 ul of mixture was then transferred  into a “spin filter tube” and centrifuged for 
1 minute. The matrix was washed 3 times with 500ul SEWS-M wash solution and 
centrifuged at 14, 500 xg for 1 minute with each wash.  Following the final wash 
the tubes were centrifuged a final time at 14, 500g for 2 minutes to “dry” the matrix 
of residual SEWS-M wash solution. 
The spin filters were then left to air dry for 2 mins before 50ul of DNase/Pyrogen 
Free Water was added. The tube was then centrifuged for 1 minute in order to elute 
the DNA.  
The quantity of DNA isolated was measured using a Nanodrop spectrophotometer 
(Thermofisher). 
 
 
 
99 
 
4.3.2 Amplification	and	sequencing	of	16S	rDNA	gene	regions	
 
All samples were sent to the Earlham Institute and DNA sequencing performed 
using the Illumina platform as per standard protocols as described in section 2.1 
(Caporaso et al., 2012) 
 
4.3.3 Bioinformatic	analysis	of	16S	rDNA	
 
Samples were analysed using Quantitative Insights Into Microbial Ecology 
(QIIME), an open-source bioinformatics pipeline for performing microbiome 
analysis from raw DNA sequencing data.  QIIME enables the analysis of raw data 
generated by sequencing platforms to generate graphics and statistics including 
taxonomic assignment, relative number of operational taxonomic units (OTUs) and 
diversity analyses. 
 
4.3.4 Preparation	of	faecal	and	urinary	samples	for	metabolomics	analysis	
 
Approximately 50 mg of frozen faecal material was transferred into a 2ml 
Eppendorf tube and kept on ice.  
Phosphate buffer solution (PBS) was made by the following specifications; 100 ml 
heavy water (D2O), Monosodium Phosphate 0.51 g, Dipotassium Phosphate 2.82 
g, Trisodium Phosphate 0.0345 g, Sodium Azide 0.1 g. 
PBS was added to the faecal material at a ratio of 12 ul/1mg.  The faecal matter 
was then homogenized with a mechanical pestle for 1 minute. This suspension  
was centrifuged for 15 minutes at 15 000 xg at 4°C  
The supernatant was transferred to a new sterile 1.5ml Eppendorf tube and then 
centrifuged for a further 15 minutes at 15 000 xg at 4°C 
The supernatant was then transferred into a new 1.5ml Eppendorf and stored at -
20° C until ready for NMR analysis. 
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Urine samples were defrosted and 2mls transferred to a sterile Eppendorf. This 
was then centrifuged at 14, 500 xg for 15 minutes at 4° C. The supernatant was 
then removed and transferred to a clean Eppendorf before analysis. 
NMR was then performed by Dr Gwen LeGall as per standard protocol (Bouatra et 
al., 2013) and the results returned for analysis.  
4.4 	 Results	
4.4.1 Patient	Demographics	
 
In total 58 volunteers were screened and consented; 19 in the control cohort, 18 in 
the Primary Biliary Cholangitis (PBC) cohort and 22 in the Primary Sclerosing 
Cholangitis (PSC) cohort. 3 were immediately excluded due to recent antibiotic or 
probiotic use. 4 control patients were excluded post colonoscopy due to pathology 
discovered at the time of endoscopy (3 for colorectal cancer, 1 for previously 
undiagnosed active inflammatory bowel disease). A further 3 did not provide faecal 
samples. Therefore 48 patients were included in the final study. The demographics 
of these volunteers is summarised in table 4.1.  
Patient Group Control (n=13) 
 
PBC (n=14) PSC (n=21) 
Mean Age 
(Years) 
64.5 (55 to 74) 
 
60.4 (45 to 78) 62.1 (33 to 77) 
Male:Female 7:6 
 
1:13 8:13 
Cirrhosis 
(Yes:No) 
0:13 5:9 4:17 
On UDCA 
(Yes:No) 
0:13 12:2 15:6 
Table 4-1 Demographics of patients included in the study. PBC = Primary Biliary Cholangitis, PSC = Primary 
Sclerosing Cholangitis, UDCA = Ursodeoxycholic acid. 
There are more volunteers in the PSC cohort. This is due primarily to volunteers in 
the control cohort being excluded for cancer and volunteers in the PBC cohort 
failing to provide samples. The average and maximum ages are comparable 
although there were 2 patients in the PSC cohort under the age of 50 and 1 in the 
PBC cohort. The predominance of females in the PBC cohort reflects the 
worldwide Male:Female ratio of 1:9  for patients diagnosed with PBC. There were 
also more females in the PSC cohort, which contradicts the national prevalence of 
2:1 although the total number of volunteers in this study was limited. 
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40 of the samples were collected directly from the patient and transported on ice 
back to the laboratory before being separated into 1 g aliquots and stored in the -
80°C freezer. 8 samples were posted directly to the laboratory using biohazard 
containers. These were then frozen directly in the collection tubes on receiving. 
The maximum length of time from providing the sample to freezing was 34 hours. 
Urine samples were frozen in the collection containers. In total 49 faecal and 38 
urine samples were collected from 48 patients. 
 
4.4.2 Metataxonomics	
 
DNA was extracted from 48 samples. The concentration of DNA measured by 
nanodrop ranged from 9.0 to 885.1 ng/ul, although more than 75% of samples 
ranged between 200 and 400 ng/ul. Samples were analysed using the QIMME 
pipeline. In total there were 5364455 high quality reads with an average of 111759 
± 29561 sequence reads per sample. 
In total 8 phyla were identified from the samples. The most abundant phylum in all 
the cohorts was Firmicutes (Figure 5.1). There is an emerging dysbiosis for 
Proteobacteria within the PSC cohort but this does not reach statistical significance 
when compared to the control (P-value = 0.17) and PBC cohorts (P-value = 0.1). 
In the PBC cohort there is a small increase in the relative abundance of 
Bacteroidetes and Actinobacteria compared to the control and PSC cohorts but 
this was not statistically significant (P-value = 0.64 and 0.19 respectively). 
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Figure 4-1 Pie charts showing relative abundance of each bacterial phylum by disease group. Each colour 
represents a bacterial phylum weighted by percentage contribution to overall bacterial population. 
In total 62 bacterial genera were identified with relative abundances of > 0.5%. 
There was a wide range of microbial diversity across all disease groups (Figure 
5.2). 
The most abundant genus in all 3 cohorts was Blautia representing 11.45% (SD 
3.46%), 13.4% (SD 8.93%) and 14.8% (SD 6.51%) for control, PSC and PBC 
respectively.   
In both the PSC and PBC group there was an increase in the genus 
Faecalibacterium when compared to the control group. Bifidobacterium and 
Bacteroides are increased in the PBC cohort which explains why there is an 
increase at phyla level in Bacteroidetes and Actinobacteria. Escherichia is 
increased in the PSC cohort thereby increasing the abundance of Proteobacteria 
in this cohort. 
 
 
103 
 
Figure 4-2 Stacked column charts showing relative abundance of each bacterial species by disease group. 
Each colour represents a bacterial species weighted by percentage contribution to overall bacterial 
population. Only those taxa that were present at >0.5% of the total bacterial population are shown 
individually. Bacteria that contributed <0.5% are shown as “Other” 
Average	bacterial	taxa	
Di
se
as
e	
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To see if these differences between controls and disease could be explained 
through development of cirrhosis and the changes in bowel integrity that develops 
as a result, the relative proportion of bacteria was compared at phyla level between 
PSC and PBC patients with cirrhosis (n = 9) and those without     (n = 24) (Figure 
5-3). 
 
 Figure 4-3 Column charts representing bacterial phyla identified in PSC and PBC patients with and without 
cirrhosis. Each colour represents a bacterial phylum weighted by % contribution to total bacterial population.  
The principal difference between the groups is a significant loss of Verrucomicrobia 
in patients with cirrhosis (2% vs 0.04% p=0.04). There is a slight increase in 
Bacteroidetes of 1.3% and a fall in Actinobacteria of 2% in the cirrhosis group. 
The effect of ursodeoxycholic acid (UCDA) on the gut microbiota composition was 
also examined. The relative proportion of bacteria were compared at phyla level 
between those PBC and PSC patients who were taking UCDA (n = 25) and those 
who were not (n = 8) (Figure 4.4). 
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Figure 4-4 Column charts representing bacterial phyla identified in PSC and PBC patients who are taking 
UDCA acid and those who are not. Each colour represents a bacterial phyla weighted by % contribution to 
total bacterial population. UDCA = Ursodeoxycholic acid. 
There is significantly larger proportion of Proteobacteria within the no UDCA cohort 
(7.5% vs 0.4%; p = 0.004). This is associated with a statistically significant larger 
proportion of Actinobacteria within the UDCA cohort (2.2% vs 9.84%; p = 0.02). 
To see if there was any similarity within the disease cohort’s, principal component 
analysis (PCoA) was performed on the 16S sequencing data (figure 4-5). This 
showed that the PSC patients had very varied microbiotas. There was also a 
separation of these patients from the PBC and control groups. The PBC and control 
cohorts showed some clustering but there is no definite separation between the 
two. 
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Figure 4-5 : PCoA analysis comparing control samples (red dots),  PBC samples (blue dots) and PSC samples 
(orange dots). Figure generated using QIIME 1.9.0 pipeline. 
To see if the patterns observed were due to other influences PCoA plots were also 
generated for presence of cirrhosis, inflammatory bowel disease, and UDCA use 
(Figures 4-6, 4-7, 4-8). None of these factors generated patterns of separation 
thereby suggesting the separation seen for the PSC cohort is not due to these 
variables.  
 
 
Figure 4-6 PCoA analysis comparing patients without cirrhosis (red dots), patient with cirrhosis (orange dots) 
and Unknown stage of liver disease (blue dots). Figure generated using QIIME 1.9.0 pipeline. 
Control	Samples	
	
PSC	Samples	
	
PBC	Samples	
No	Cirrhosis	
	
Cirrhosis	
	
Unknown	liver	stage	
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Figure 4-7 PCoA analysis comparing patients with inflammatory bowel disease (blue dots) and patients 
without inflammatory bowel disease (red dots). Figure generated using QIIME 1.9.0 pipeline.  
 
 
Figure 4-8 PCoA analysis comparing patient use of UDCA (blue dots) to those not taking UDCA (red dots). Figure 
generated using QIIME 1.9.0 pipeline. 
	
4.4.3		 Metabolomics	
 
To assess if metabolites varied between sample groups and thereby could have a 
role to play in pathogenesis disease, metabolomic analysis was performed on 
faecal water and urinary samples. In total 49 faecal samples (13 control samples, 
15 PBC samples and 21 PSC samples) and 38 urine samples (21 PSC samples, 
11 PBC samples and 6 control samples) were analysed. The full results for the 89 
metabolites are given in Appendix 3. In faeces the most abundant short chain fatty 
No	Inﬂammatory	Bowel	Disease	
	
Inﬂammatory	Bowel	Disease	
No	UCDA	use	
	
UCDA	use	
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acids were Acetate (average concentrations 59.25 mmol/kg) and butyrate (average 
concenetration 17.11 mmol/kg) and the most abundant amino acid was Glutamate 
(average concentration 3.58 mmol/kg). In urine the concentrations of metabolites 
were much lower. Creatinine was the most abundant compound (average 
concentration 7.822 mM/kg). Glucose was also relatively abundant (average 
concentration 1.96 mM/kg) but patients with diabetes may skew this.  The 
concentrations of short chain fatty acids and amino acids were in keeping with the 
published data  (Bouatra et al., 2013; Fernandes et al., 2013; Francavilla et al., 
2012; Rahat-Rozenbloom et al., 2014). 
PCoA plots were generated using the metabolomic data (Figures 4-9, 4-10, 4-11). 
These do not show any separation between the disease groups or the controls. 
This mirrors the metataxonomic data whereby only subtle shifts are seen between 
the three groups. 
 
Figure 4-9 PCoA of faecal metabolomic data obtained through nuclear magnetic resonance spectroscopy 
(NMR). Figure provided by Dr Gwen Le Gall. PBC =Primary Biliary Cholangitis, PSC = Primary Sclerosing 
Cholangitis 
Disease	1	
	
Disease	2	
	
Control	
 
PBC 
PSC 
Control 
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Figure 4-10 PCoA of urinary metabolomic data obtained through nuclear magnetic resonance spectroscopy 
(NMR). Figure provided by Dr Gwen Le Gall. PBC =Primary Biliary Cholangitis, PSC = Primary Sclerosing 
Cholangitis 
 
4.5 Discussion	
 
Previous studies have suggested that alterations in the microbiota have a crucial 
role to play in the development of chronic liver disease (Sabino et al., 2016; 
Tuomisto et al., 2014; Zhu et al., 2013). In this chapter the gut microbiota of 
patients with PBC and PSC was assessed through a 16S rDNA sequencing 
approach. At phyla level the relative abundance Bacteroidetes and Acintobacteria 
were slightly increased in the PBC cohort, although this does not reach statistical 
significance. A recent study looking at treatment of naïve PBC patients reported 
that Bacteroidetes was decreased when compared to healthy controls, with a 
corresponding over-representation of Proteobacteria and Fusobacterium (Tang et 
al., 2017). At genus level,  an increase in Bacteroides and Faecalibacterium was 
observed, whereby in the study by Tang et al (2017) there was an increase in 
Streptococcus, Klebsiella, Pseudomonas and Haemophilus. 
In comparison, previous studies have reported an increase in Bacteroidetes and 
Fusobacterium, with a decrease in Firmicutes, in patients with PSC (Quraishi et 
al., 2017; Sabino et al., 2016), whereby this study reports an increase in 
Proteobacteria, largely due to an increase in Escherichia. This compares to 
Disease	1	
	
Disease	2	
	
Control	
 
PBC 
PSC 
Control 
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another study that showed Escherichia was increased in patients with Non-
alchololic steatohepatitis (Zhu et al., 2013). Interestingly the study by Sabino et al 
(2016) also reported a less significant increase in Bacteroidetes and 
Faecalibacterium in patients with UC alone when compared to healthy controls, 
whereas other studies have reported a decrease in Bacteroidetes and Firmicutes 
(Rossen et al., 2015). 
The data presented in this chapter reflects the problems associated with microbiota 
research in that sampling can only ever provide a snap shot of the bacteria within 
the gut at any given time. There are multiple factors that can affect the microbiota 
from day to day including medications, infections, antibiotics and diet. Therefore 
there is great variability between subjects and samples, which leads to conflicting 
results between publications being produced.  Larger numbers of patients with 
repeated sample collections over time would give a better reflection on the stability 
of the gut microbiota in these conditions. 
The studies in PSC and PBC so far have not accounted for the stage of liver 
disease. There is now good evidence that end stage liver disease and portal 
hypertension may cause alterations in gut permeability and alterations in gut 
microbiota through prolonged gut transit and small bowel bacterial overgrowth 
(Reiberger et al., 2013; Kalaitzakis, 2014). Therefore this study examined the 
differences between patients with PBC/PSC and cirrhosis and those without. The 
principle findings were that Verrucomicrobia was not detected and Fusobacteria 
became slightly more apparent in the cirrhosis group. Although the 
Verrucomicrobia result was skewed by a single patient sample it is interesting to 
note that 6/13 control patients and 7/23 non- cirrhotic patients had abundances of 
Verrucomicrobia of greater that 1.5% all due to the presence of Akkermansia sp, 
whereas the cirrhosis patients had a maximum abundance of 0.1%. This bacterium 
is the sole representative of Verrucomicrobia in human stools and has been shown 
to be depleted in patients with diabetes and obesity, both of which are risk factors 
for liver disease (de Vos, 2017). It promotes beneficial interactions with the host 
through signalling immune and metabolic pathways (de Vos, 2017). Therefore, it 
is possible that this is a significant result that requires further investigation. 
Until recently UDCA has been the only approved treatment for PBC (Rudic et al., 
2012). It is thought that its effect is through displacement of endogenous 
hepatotoxic bile through expansion of the hydrophilic bile acid pool (Stiehl et al., 
1999), although its exact mechanism of action is unclear. It is a secondary bile acid 
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produced by intestinal bacteria and unabsorbed UDCA undergoes further 
transformation to lithocholic acid by colonic bacteria (Kullak-Ublick et al., 2000). 
Due to this it is possible that the UDCA may have an effect on dysbiosis associated 
with chronic liver disease. A recent study has looked at this particular hypothesis 
by examining treatment naïve PBC patients and examining faecal microbiota 
before and after UDCA. They showed that treatment with UDCA resulted in partial 
amelioration of gut dysbiosis, in particular Haemophilus, Streptococcus and 
Pseudomonas sp were decreased (Tang et al., 2017). In this chapter it has been 
shown that the most marked differences in microbiota are seen when patients 
taking UDCA are compared to those that are not. There is a significant decrease 
in the relative abundance of Proteobacteria in the UDCA cohort. Although these 
are not comparing the same patients this result reflects the findings published by 
Tang et al. (2017).  This suggests that UDCA has a positive effect on dysbiosis, 
although whether this is due to a direct impact on harmful bacteria or because 
beneficial bacteria are able to utilize UDCA to aid proliferation is not clear. The 
effect of UDCA may also be the reason that greater changes were not seen 
between the control group and patients with disease. Future work could include 
using the in vitro colonic model to see if UDCA has a direct affect on the faecal 
microbiota, or whether this is an effect generated by interactions with the host. 
The interaction between cholestatic liver disease, bile salts and the gut microbiome 
is likely to be a complex one involving some of the pathways described in figure 
1.5. It is possible that it involves a 2- way process with changes in the microbiota 
effecting metabolic pathways through alterations in bile salts on the one hand and 
changes in expression of pathways such as FXR due to genetic predisposition 
causing changes in bile salt synthesis/reabsorption which alter microbiota on the 
other. 
One of the reasons that these results do not fully mirror previous studies may be 
due to means by which samples were transferred and stored. Several of the 
samples were delivered via post and therefore not kept on ice. Equally all the 
samples were frozen until required and DNA not extracted directly from fresh 
samples. There is therefore the possibility that DNA within the samples is 
progressively denatured during transport and on thawing from frozen. Recent 
studies however have shown that technical reproducibility and stability within 
samples is generally high when samples are frozen immediately or incubated at 
room temperatuere for 96 hours and then stored (Vogtmann et al., 2017). There 
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are also comparable cure rates for Clostidium difficile infection when frozen and 
fresh faecal microbial transplants are used (Jiang et al., 2017). 
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5 General	Discussion	
5.1 Summary	of	results	and	completion	of	aims	
 
The gastrointestinal tract in humans is home to 100 trillion bacteria. This complex 
bacterial organ forms an important symbiotic relationship with the host and has 
been shown to be vital in health. Alterations in the microbiota structure and function 
can occur due to environment, diet, infections, disease and drugs. Equally 
alterations, or dysbiosis, within the microbiota are linked with a number of 
gastrointestinal and non- gastrointestinal diseases, with emerging evidence that 
this dysbiosis can induce or interfere with host pathways and therefore cause 
pathogenesis, and not simply occur as a result of  disease. 
The liver receives 70% of blood flow directly from the gut. The biliary system also 
drains directly into the small intestine. Therefore the liver is continuously exposed 
to bacterial components from the gut. As such the gut microbiota has been linked 
to the pathogenesis of several liver conditions including alcoholic liver disease, 
non-alcoholic steatohepatitis and primary sclerosing cholangitis. Biliary diseases 
such as cholesterol gallstones are thought to have a bacterial trigger. However 
there is little data on the normal biliary system and to date no studies have 
accurately assessed if there is a normal biliary tract microbiota. 
The overall aim of this study was to determine whether a biliary microbiota exists, 
its complexity and whether bacteria isolated from the biliary tree have the 
properties required to survive in this environment. The faecal microbiota from 
patients with Primary Biliary Cholangits and Primary Sclerosing Cholangitis, two 
chronic auto-immune biliary conditions, was also examined to see if there was any 
dysbiosis that could be linked to biliary damage 
 
5.1.1 Aim	1:	“To	see	whether	bile	isolated	from	the	normal	biliary	tract	is	truly	
sterile”	
 
Bacteria were repeatedly and successfully isolated from both the diseased and 
normal human biliary tract. The predominant species were Bacillus, Micrococcus, 
Enterococcus and Staphylococcus.  Bacterial DNA was also successfully extracted 
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from biliary samples from healthy and diseased status for 16S-based 
metataxonomic analysis that revealed a diverse microbial population. This also 
highlighted that many of the bacteria within the human biliary tract that could not 
be cultured using standard microbiological growth media. . The predominant 
species identified in both normal and diseased biliary tract was Pseudomonas. The 
findings confirm for the first time that there may be  a core biliary microbiota. 
5.1.2 Aim	2:	“To	see	if	there	is	a	difference	in	microbial	biodiversity	between	
bile	isolated	form	diseased	and	normal	biliary	tracts”	
 
Bile isolated from the normal gallbladder showed the greatest biodiversity. There 
was an emerging dysbiosis for Enterococcus within the diseased gallbladder 
group. Pseudomonas was the predominant species in all four diseased groups, 
especially within the normal common bile duct group.  
5.1.3 Aim	3:	“To	assess	whether	bacteria	isolated	from	the	biliary	tract	have	
bile	resistant	properties”	
 
A small proportion of bacteria, predominantly isolated from the diseased 
gallbladder, were able to proliferate in the presence of high dose bile salts. The 
other bacteria were all able to survive in physiologically relevant concentrations of 
bile salts. A subset of bacteria were able to proliferate following an initial decline 
suggesting that these bacteria were able to induce pathways to utilise bile salts. 
Some of the bacteria were shown to express bile salt hydrolase (BSH), an enzyme 
that deconjugates bile salts which may aid in the bacterial resistance to bile salts . 
Others were able to survive without BSH activity, thereby suggesting alternative 
mechanisms for bile salt resistance. 
5.1.4 Aim	 4:	 “To	 investigate	 changes	 in	 microbial	 biodiversity	 between	
Primary	 Biliary	 Cholangits	 (PBC)	 and	 Primary	 Sclerosing	 Cholangitis	
(PSC)	when	compared	to	healthy	controls”	
 
There was a higher proportion of Proteobacteria in the gut microbiota within the 
PSC cohort when compared to healthy controls. There was also a higher 
proportion of Bacteroidetes and Actnobacter within the PBC cohort. At genus level 
there was a relative abundance of Escherichia in the PSC cohort and Bacteroides 
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and Bifidobacterium in the PBC cohort. None of these findings reached statistical 
significance. There was a great deal of individual variablility within the 3 cohorts. 
 
5.1.5 Aim	5:	“To	see	if	treatment	and	stage	of	liver	disease	has	an	impact	on	
faecal	microbiota”	
 
Patients with cirrhosis had no detectable levels of Akkermansia species within 
samples when compared to controls and patients with only fibrosis. This bacterium 
is known to play a beneficial role has a role to play in gut health and may be a 
significant finding in terms of understanding increased gut permeability and 
translocation seen in cirrhosis and portal hypertension. 
There was a statistically significant change between patients taking UDCA and 
those that did not. Patients on UCDA had significantly more Actinobacter and less 
Proteobacteria when compared to patients not taking this medication. UDCA may 
also be the reason that a greater difference was not seen between patients with 
cholestatic liver disease and controls. 
 
5.1.6 Aim	6:	“To	assess	the	metabolic	activity	of	the	gut	microbiota	in	PBC	and	
PSC”	
 
There were no significant differences between the metabolomic profile of patients 
with disease and healthy controls. This corresponds with the microbiota findings 
that produced no statistically significant differences in the metataxonomics 
between the groups.  
 
5.2 Future	Work	
 
This study was aimed at proving if there was a core biliary microbiota. Having 
shown that such microbiota exists, that it is now important that this work is carried 
on to see how this extension of the bacterial organ has a role in the pathogenesis 
of disease. The study has raised many questions that require future research to be 
able to answer. Having identified that Pseudomonas is a prevalent species within 
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the normal biliary tract research can now focus on what interactions it has with the 
host and whether it has a role in immune mediated pathways. Several other 
bacteria have been isolated which previously had not been considered important 
in the pathogenesis of liver disease and may have a role to play. The most obvious 
of these is Staphylococcus, which is often a considered a contaminant. However, 
it is frequently isolated from GI and biliary studies and may be an important 
bacterium to study. A core microbiota has been identified but it is not clear whether 
alterations to this can cause or prevent disease. Manipulation of this microbiota 
through probiotics and antibiotics could provide further insight into the 
pathogenesis of biliary and liver disease.  
The way in which these bacteria utilise and survive in bile salts may provide a 
therapeutic option for cholestatic disease. The bacteria isolated could be 
inoculated into media containing bile salts and the total concentrations of bile salts 
and metabolites measured following growth, thereby providing a mechanism 
through which interactions with the host take place. UDCA is a secondary bile acid 
and obeticholic acid (OCA) is a powerful FXR agonist. Both of these drugs have 
clear potential to interact with the gut microbiota and should be studied further in 
this context. It would be possible to examine these compounds using the in vitro 
colonic model to see if they cause direct changes to the microbiota or whether the 
effect seen is because of interactions with the host. 
The finding that Akkermansia is reduced in cirrhotic patients is an interesting 
discovery from this study. It already has links to diabetes and obesity and clearly 
looks like it may have a role to play in the pathogenesis of liver disease. It would 
be interesting to see if the metabolic pathways these bacteria are associated with 
may play a role in the prevention of cirrhosis. 
Finally, this study has isolated several fungi from the biliary tract. To date there is 
limited data on the role fungi have in the development of liver, biliary or 
gastrointestinal disease. It would be possible to identify these fungi through 
sequencing of their 18S rDNA and this ‘mycobiomics’ needs further research. 
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5.3 Conclusion	
 
The work presented in this study provides evidence that there is a normal diverse 
biliary microbiota that alters with disease. Some of the bacteria isolated from the 
biliary tracts are able to utilise bile salts that may aid their survival and thereby 
provide a potential therapeutic target that requires further investigation. Treatment 
for chronic liver disease has an impact on the gut microbiota further highlighting 
the importance of the gut-liver axis in our understanding of liver disease. 
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Introduction 
 
The gastrointestinal tract in humans is home to 100 trillion bacteria with at least 
1000 different bacterial species (Shanahan, 2012). In the last decade research 
has begun to focus on this bacterial “organ” to see if it has an impact on the 
pathogenesis of disease. Many auto-immune conditions are thought to have an 
inflammatory or infective trigger so it is conceivable that changes in the gut 
microbiome could play a role in the development of some auto-immune disease. 
In Crohns disease it has been shown that there is abnormal microbial 
composition, increased mucosal-associated bacteria (Sartor, 2008) and that 
exposure to intestinal contents causes recurrent disease after loop ileostomy 
(D’Haens et al., 1998). It has been shown that there is a loss of biodiversity of the 
bacterial species (Noor et al., 2010) and an altered metabolic activity of the gut 
microbiota in patients with ulcerative colitis (Le Gall et al., 2011). A similar finding 
has been found in early rheumatoid arthritis with proportionally less bacteria, 
especially Bifidobacterium species, when compared to fibromyalgia patients 
(Vaahtovuo, Munukka, Korkeamaki, Luukkainen, & Toivanen, 2008). Increased 
intestinal permeability and increased intestinal lymphocytes have also been cited 
as possible causes in the pathogenesis of Type 1 diabetes and Hasimoto’s 
thyroiditis (Mori, Nakagawa, & Ozaki, 2012; Bosi et al., 2006). 
 
The liver receives 70% of its blood supply directly from the gastrointestinal tract 
via the portal vein. This results in continual exposure to gut bacteria and bacterial 
cell components and metabolites (Son, Kremer, & Hines, 2010). Indeed small 
bowel bacterial overgrowth has been associated with bacteraemia in 
spontaneous bacterial peritonitis (SBP) and hepatic encephalopathy and 
antibiotic therapy is a mainstay of treatment in the management and prevention 
of a number of complications of chronic liver disease (Quigley, Stanton, & 
Murphy, 2013). It is therefore conceivable that this complex gut microbiome has 
an important role in the development of chronic liver disease via this “gut-liver 
axis” and recent research has begun to explore this hypothesis. Recently it has 
been shown that there is a significant difference in the composition of the gut 
microbiome between cirrhotics and healthy controls with a significant increase in 
Enterocoocus and Enterobacteriaceae species (Liu et al., 2012). Changes in the 
microbiota have also been identified in non-alcohol related fatty liver disease, 
alcohol related liver disease and intestinal failure associated liver disease 
(Quigley et al., 2013). 
 
The aim of this thesis is to expand our knowledge of the gut microbiome and its 
association with liver and biliary disease, in particular the pathogenesis of 
primary biliary cirrhosis (PBC), the impact of antibiotics in chronic liver disease 
and the investigation of bile especially the possibility that it is not sterile and may 
have a role in the composition of the gastrointestinal microbiome. The thesis will 
therefore be undertaken in 3 parts which are discussed below. 
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1. Is Bile Sterile? 
 
Summary 
 
Aim 
 
Conventional wisdom dictates that bile is sterile. However, recent studies have 
identified bacterial populations within the gallbladder, gallstones and bile of 
symptomatic patients undergoing cholecystectomy. It is therefore feasible that 
bacteria are present within healthy individuals and this may a role in the 
development of liver and biliary disease. The aim of this study is to analyse bile 
from patients undergoing liver resection, cholecystectomy or pancreatectomy to 
assess whether bile is truly sterile. 
  
Approach 
 
A prospective study of the bacterial composition of bile sampled at the time of 
elective biliary surgery. Metaxonomic analysis will be performed on any positive 
growth. Bile resistance studies will also be performed on positive colonies to 
assess whether they have pathogenic potential. Metabolomic analysis will also 
be performed using NMR and LC-MC 
 
Study population 
 
Patients undergoing elective liver resection, pancreaticoduodenectomy 
(Whipple’s procedure) and laparascopic cholecystectomy for gallstone disease. 
 
 
Scientific background 
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It has now been established that cholesterol gallstones contain bacteria 
(Monstein, Jonsson, Zdolsek, & Svanvik, 2002) and bacteria including H. pylori 
has been detected within the mucosa of diseased gallbladders (Griniatsos et al., 
2009). More recently studies have identified a diverse bacterial community within 
the bile of gallstone patients (Wu et al., 2013) and within diseased pancreatic 
ducts and biliary stents (Swidsinski et al., 2005). To date studies have been 
unable to culture bacteria directly from bile and no studies have assessed bile 
from patients not known to have biliary infection. The pathogenesis of 
hepatobiliary diseases such as PBC and primary sclerosing cholangitis are 
thought to include an infectious trigger (Pollheimer, Halilbasic, Fickert, & Trauner, 
2011) although studies have failed to show any significant bacteriaemia in 
mesenteric and peripheral blood samples (Weismuller, Wedemeyer, Kubicka, 
Strassburg, & Manns, 2008). The immune response in PBC is restricted to the 
epithelial cells of the intrahepatic ducts (Selmi, Bowlus, Gershwin, & Coppel, 
2011). It is therefore possible that bile is not sterile and  may contain bacteria 
which could trigger disease in genetically susceptible patients. 
As gallbladders are routinely removed during liver resections and the bile duct 
swabbed during pancreatic cancer resection we have the opportunity to sample 
and examine sterile bile using new sequencing technology to assess whether the 
human micro biome also has a role in liver and biliary disease. 
 
 
Objectives 
 
Overall objective 
 
To assess whether “normal” bile is sterile. 
 
Specific objectives 
 
1) To culture “normal” bile.  
2) To identify bacteria within bile through DNA extraction and 454 sequencing 
3) To assess whether patients with cholelithiasis have bacterial colonization of 
bile 
1. If bacteria are cultured, to assess their resistance to bile salts 
2. To obtain information regarding the metabolic activity of bacteria within bile. 
 
 
Study design 
 
Recruitment policy 
 
Patients under the care of Mr Weymss-Holden (Consultant hepato-biliary 
surgeon at the Norfolk and Norwich University Hospital) and Mr Harper 
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(Consultant  hepato-biliary surgeon at Addenbrookes Hospital, Cambridge) 
undergoing liver resection and cholecystectomy, laparoscopic cholecystectomy 
or a  pancreatectomywill be approached and consented pre-operatively.  
 
Screening criteria 
 
All patients undergoing elective liver resection and cholecystectomy, 
laparoscopic cholecystectomy  or pancreatectomy procedure at the Norfolk and 
Norwich University Hospital or Addenbrookes hospital. 
 
Basic Exclusion Criteria 
 
Emergency procedures. 
Current septicaemia. 
Previous biliary sepsis 
 
Screening Exclusion Criteria 
 
Biliary intervention which would may increase the risk of colonization of the biliary 
tree such as biliary stents and sphincterotomy. 
Inability to perform liver resection/ surgery such as disease progression. 
Current antibiotic use or antibiotics within previous 30 days. 
Current probiotic use or probiotic use within previous 30 days. 
 
Procedures and timelines 
 
Recruitment and samples will be collected between April 2013 and April 2015 
Processing of the samples will be completed by January 2016. 
 
 
Methods 
 
Sampling 
 
Bile samples will be collected at the time of surgery from resected gallbladders. 
This will be done under sterile conditions with the bile being placed in the sterile 
containers (which have previously been kept in anaerobic conditions for a 
minimum of 24 hours) for transport to the laboratory for processing. 
 
Processing 
 
Bile will be immediately inoculated onto different media both aerobically and 
anaerobically. Growth will be assessed at 24 and 48 hours. Colonies will be 
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separated and regrown before undergoing single colony 16S PCR. RNA will then 
be purified before being sent for 454 sequencing. 
The remaining bile will then be frozen at -80C to preserve DNA before 
undergoing DNA extraction using the modified Qiagen protocol. 
Glycerols will be taken of all colonies and stored at -80C for future investigation. 
 
Analysis 
 
Metaxonomic analysis on sequenced samples will be analysed using the QIIME 
computer programme to provide details of composition and quantitive 
measurement of the microbiota.  
Bile resistance studies will be performed on colonies using the bioscreen and 
recording growth curves over 48 hours in increasing concentration of bile salts up 
to 10% to mimic the concentrations experienced in the gall bladder. 
Metabolomic analysis will be by NMR and LC-MC 
 
 
 
 
 
 
 
 
 
 
 
 
1. Primary Biliary Cirrhosis 
 
Summary 
 
Aim 
 
The aetiology of primary biliary cirrhosis (PBC) is unclear but there is increasing 
evidence that the faecal microbiota plays an important role in the development of 
auto-immune disease and chronic liver disease. The aim of this project is to 
assess the faecal microbiota in PBC patients with and without cirrhosis as 
compared to controls. I also aim to look at the impact ursodeoxycholic acid has 
on the faecal microbiome, which may aid understanding of the mechanism of 
action for this drug. 
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Approach 
 
This will be a prospective study with faecal and urine samples being collected 
from patients with PBC with and without liver cirrhosis. Bacterial DNA will be 
extracted from these samples and undergo metaxonomic and metabolomic 
analysis. These results will then be compared to age-matched controls. 
 
 Population 
 
Patients with primary biliary cirrhosis will be selected from the liver database at 
the Norfolk and Norwich Hospital. Age-matched controls will then be selected 
from the tissue bank database. 
 
Scientific background 
 
The prevalence of primary biliary cirrhosis (PBC) has been increasing over the 
past 30 years and is now a significant cause of liver morbidity and mortality. The 
aetiology remains unclear although there is a clear auto-immune and genetic 
component as suggested by a weak association with HLA-B8, the discovery of 12 
new susceptibility loci on genome-wide association studies (Mells et al., 2011), its 
association with extra hepatic autoimmune disease and a high concordance rate 
in monozygotic twins (Selmi et al., 2011).  Several infectious and environmental 
factors are thought to contribute to the onset of PBC, as evidenced by clustering 
of cases near toxic waste sites in New York, the significantly higher rate of 
urinary tract infections in patients with PBC (Varyani, West, & Card, 2011) and 
the demonstration of molecular mimicry between mitochondrial and nuclear auto 
antigens in PBC (Shimoda et al., 2003). Given that PBC is a chronic inflammatory 
disorder it is possible that exposure to bacteria in a genetically susceptible 
individual may precipitate the development of the condition. Both pathogenic and 
non-pathogenic Gram-negative bacteria have been proposed but as yet not 
substantiated (Selmi et al., 2011). Through this study it may be possible to detect 
changes in the human microbiome in PBC patients which may provide further 
evidence to an infectious cause. At present treatment options for PBC are limited. 
Ursodeoxycholic acid (UDCA) isthe only treatment that has approval, but studies 
have shown that although it improves liver biochemistry and histological 
progression, it may have no effect on mortality, progression to liver 
transplantation or symptoms (Rudic, Poropat, Krstic, Bjelakovic, & Gluud, 2012). 
If a link between the gut microbiota and primary biliary cirrhosis can be 
established then it may open doorways to novel treatment strategies which could 
prevent and possibly treat established disease. 
 
 
Objectives 
 
Overall objective 
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To assess the role of the colonic microbiota in the pathogenesis of primary biliary 
cirrhosis. 
 
Specific objectives 
 
1) To perform quantitive assessment of the composition and phylogenic data of 
the gut microbiota in patients with PBC 
2) To establish if the metabolite profiles derived from blood and urine samples 
can be correlated with differences in bacterial metabolism in PBC patients 
3) To assess if the use of UCDA has an impact on the composition of the gut 
microbiota of patients with PBC. 
 
 
Study design 
 
Recruitment policy 
 
Patients will be selected from the hepatology database at the Norfolk and 
Norwich University. They will then be invited to participate via letter with 
subsequent phone call to confirm participation. Patients may decline via e-mail or 
phone call at the time of receipt of the letter or at the time of follow up phone call. 
A meeting will be organised with those patients who wish to participate where a 
detailed explanation of the study and process for sample collection will take 
place. 
Controls will age matched from samples collected in the tissue bank. 
 
Screening Criteria 
 
All patients identified as having PBC according to hepatology hospital database 
who live within 45 mins of the hospital. These patients will then be subdivided 
into those with cirrhosis and those without. 
Basic Exclusion Criteria 
 
Age > 80 or <18 
Current antibiotic therapy 
Concurrent liver disease of another aetiology 
 
Screening Exclusion Criteria 
 
Current antibiotic use including rifaximin and rifampicin 
Antibiotic use within the last 30 days. 
Current inclusion in banding programme. 
Current diarrhoeal illness or diarrhoea within 2 weeks. 
Current or recent use of laxatives within 30 days. 
Acute decompensation and hospital admission within 30 days. 
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Procedures and Timelines 
 
 
Recruitment and samples will be collected between April 2013 and April 2015. 
Processing of samples will be completed by January 2016. 
 
 
Methods 
 
Sampling 
 
Arrangements will be made with patients at the time of consent for sample 
collection. This will either involve collecting the sample or delivery to the institute 
of food research by the participant. All samples will be delivered within 2 hours 
for processing. 
 
Processing 
 
Stool samples will be collected in sterile tubes and immediately stored at -80C 
until analysis. Total bacterial DNA will be extracted using the modified Qiagen 
soil protocol. The integrity of the nucleic acids will be determined visually using 
electrophoresis on 1% agarose gel containing ethidium bromide. Samples will 
then be sent for 454 sequencing. 
 
Analysis 
 
Metaxonomic analysis on sequenced samples will be analysed using the QIIME 
computer programme to provide details of composition and quantitive 
measurement of the microbiota. This programme will also provide information on 
the differences between PBC patients and controls. 
Metabolomic analysis will be by NMR and LC-MC. 
 
 
 
 
3. What is the evidence for prophylactic antibiotic 
use in increasing survival in cirrhosis? 
 
 
Antibiotics are routinely used in prophylactic treatment of complications of 
cirrhosis such as variceal bleeding (Jalan & Hayes, 2000), spontaneous bacterial 
peritonitis (Moore & Aithal, 2006) and hepatic encephalopathy (Mullen et al., 
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2013). It is also common practice to use antibiotics in acute liver failure (Lai, Lee, 
Han, & Kim, 2004). This is because patients with acute liver failure and acute 
decompensation of cirrhosis are prone to infection, especially Staph. aureus and 
E. coli, due to host defence mechanisms being impaired (Borzio et al., 2001). 
Despite this antibiotics are not routinely recommended in guidelines as there is 
uncertain survival benefit (Polson & Lee, 2005). The aim of this chapter is to 
perform a meta-analysis looking specifically at the role of prophylactic antibiotics 
in terms of survival in cirrhosis. 
 
 
 
Ethical Approval 
 
All aspects of this study have received ethical approval from the Faculty of 
Medicine and Health Research Ethics Committee, University of East Anglia 
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Appendix	2:	SOP	for	bile	salt	analysis	
 
BILE ACID (BA) ANALYSIS FROM LIVER AND INTESTINAL SCRAPES 
 
BA standards 
d4 Internal standards 
Each d4 internal standard is prepared at 1 mg/ml in MeOH 
Prepare 5 solutions of these all at 40 µg/ml by taking 400µl of each stock standard to 10 
ml in 70% MeOH 
INT Std # Int Std(s) 
1 d4-GCA + d4 LCA 
2 d4-CA 
3 d4-CDCA 
4 d4-DCA 
5 d4-DCA/CDCA/CA/GCA/LCA 
 
Calibration standards 
Each BA is prepared at 1 mg/ml in MeOH and stored refrigerated. 
Note: most are supplied as salt hydrates which must be taken into account when 
weighing out the standard. 
A 10 µg mix of the BAs is prepared in 70% MeOH by taking 100 µl of each individual BA 
(at 1 mg/ml) into a pooled vial and making to 10 ml total volume. 
Make all calibration standards to total volume of 500µl with methanol. 
Note – where subsequent dilution made, you need to prepare 2 of these standards. 
Std (ng/ml) Vol (µl) Of what std Make up vol (µl) 
(MeOH) 
Notes 
4000 200 10 µg/ml mix 300  
2000 100 10 µg/ml mix 400  
1000 50 10 µg/ml mix 450 Prep x 2 
500 25 10 µg/ml mix 475  
200 10 10 µg/ml mix 490  
100 50 1000 ng/ml mix 450 Prep x 2 
25 12.5 1000 ng/ml mix 487.5  
15 75 100 ng/ml mix 425  
10 50 100 ng/ml mix 450  
5 25 100 ng/ml mix 475  
0 0 - 500  
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Then to each of these, add 25µl of d4-Int Std mix #5 (40 µg/ml) to give 2000 ng/ml each. 
BA standard identities 
BIOCHEMICAL Abbrev Cat# Supplier IFR# 
Chenodeoxycholic acid CDCA C9377 Aldrich 85 
Deoxycholic acid DCA D2510 Aldrich 90 
Dehydrocholic acid DHCA 30830 Aldrich 348 
Glycocholic acid GCA G2878 Aldrich 144 
Glycochenodeoxycholic acid GCDCA G0759 Aldrich 146 
Glycodeoxycholic acid GDCA G9910 Aldrich 143 
Lithocholic acid LCA L6250 Aldrich 179 
Taurocholic acid TCA T4009 Aldrich 262 
Taurochenodeoxycholic acid TCDCA T6260 Aldrich 264 
Taurodeoxycholic acid TDCA T0895 Aldrich 263 
Ursodeoxycholic acid UDCA U5127 Aldrich 267 
Taurolithocholic acid TLCA T7515 Aldrich 265 
α-Muricholic acid a-MCA C1890-000 Steraloids 340 
β -Muricholic acid b-MCA C1895-000 Steraloids 338 
Cholic acid CA C1900-000 Steraloids 86 
Glycolithocholic acid GLCA C1437-000 Steraloids 330 
Hyodeoxycholic acid HDCA C0885-000 Steraloids 156 
Muricholic acid MCA C1850-000 Steraloids 335 
Tauro-α-Muricholic acid T-a-MCA C1893-000 Steraloids 333 
Tauro- β -Muricholic acid T-b-MCA C1899-000 Steraloids 332 
Glycohyocholic acid GHCA C1860-000 Steraloids 345 
Glycoursodeoxycholic acid GUDCA C1025-000 Steraloids 341 
Taurohyocholic acid THCA C1887-000 Steraloids 342 
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Taurohyodeocycholic acid THDCA C0892-000 Steraloids 343 
Tauroursodeoxycholic acid TUDCA C1052-000 Steraloids 344 
Glycohyodeoxycholic acid GHDCA C0867-000 Steraloids 346 
Taurodehydrocholic acid TDHCA C2047-000 Steraloids 347 
DEOXYCHOLIC ACID -D4 d4-DCA C1070-015 Steraloids  
LITHOCHOLIC ACID -D4 d4-LCA C1420-015 Steraloids  
CHOLIC ACID-D4 d4-CA C1900-015 Steraloids  
GLYCOCHOLIC ACID -D4 d4-GCA C1925-015 Steraloids  
CHENODEOXYCHOLIC ACID -D4 d4-CDCA C0940-015 Steraloids  
 
 
  
158 
 
Solutions required 
70% Methanol 
5% Methanol 
Methanol 
 
Sample preparation Liver extracts 
Take 50mg (record weight) liver tissue in 2 ml screw cap tube + 4-6 1.4mm ceramic 
beads 
Add 1 ml ice cold 70% MeOH 
Add 25 µl of Int Std #4 (so is present at 1000 ng/ml) 
Homogenise 30s 6000 (prog 4 in Precellys) 
Centrifuge 5 min 3000 rcf 4°C 
Take supernatant to new 1.5ml Eppendorf tube 
Add 25 µl of Int Std #3 
Rotary evaporate at 50°C for 70 minutes (removes the MeOH content) 
This will not be to dryness, but make up by eye in eppendorf tube scaling to 1 mL with 
5% MeOH 
Add 25 µl Int Std #2 
 
Solid Phase Extraction (SPE) Clean-up 
Clean-up is via Waters OASIS PRIME HLB 1 30mg SPE cartridges. 
Install cartridges into SPE vacuum system. 
Load sample onto tube. 
Engage vacuum as low as possible.  Some tubes will empty quicker than others, but 
minimum of 3 minutes to empty tube and collect to waste.  
As each tube becomes empty, close it off and increase vacuum as necessary with care to 
allow all remaining tubes to empty.   
Once all empty, decrease vacuum and open all tubes.  Re-apply vacuum to dry cartridges 
applying moderate vacuum for 2 minutes. 
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Vacuum off and close cartridges. 
Wash with 1 ml of 5% MeOH  
Apply same elution and dry procedure as above ensuring cartridges are dry. 
Discard washings and replace collectors with labelled 1.5 ml Eppendorfs 
Elute with 500 µl 100% MeOH using same procedure. 
Add 25 µl of Int Std # 1 to eluate. 
Summary of SPE 
• Load sample (1 ml) 
• Wash with 1 ml 5% MeOH 
• Elute with 1 ml MeOH 
 
The issue here is not to allow solutions to pass through too quickly.  Different tubes 
elute at different rates so the vacuum is adjusted accordingly. Note there is no cartridge 
conditioning step necessary with this product. 
Transfer samples to low volume autosampler tubes for LC-MS analysis. 
 
LC-MS 
Conditions 
Column : Supelco Ascentis Express C18 150 x 4.6, 2.7µm 
Flow: 600 µl/min 
Mobile phase A : Water + 5mM Amm. Ac + 0.012% Formic acid 
Mobile Phase B: Methanol + 5mM Amm. Ac + 0.012% Formic acid 
Inj: 5µl 
Column: 40°C 
Mobile phase preparation 
In one litre of MeOH or Water: 
5 mM Ammonium Acetate = 0.385g 
0.012% formic acid = 120 µl 
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LC Gradient 
Time %B 
0 50 
2 50 
20 95 
24 95 
25 50 
29 50 
 
Source Conditions (negative mode) 
SOURCE 
 
CUR:  25 
TEM:  550 
GS1:  40 
GS2:  50 
ihe:  ON 
CAD:  -2 
IS:  -4500 
EP -10 
CXP -9 
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MRM settings 
ID Q1 Q3 Dwell DP CE RT 
LCA 375.3 375.3 20 -90 -10 22.7 
CDCA 391.3 391.3 20 -120 -10 20.85 
DCA 391.3 391.31 20 -120 -10 21.17 
HDCA 391.3 391.32 20 -120 -10 18.29 
MCA 391.3 391.33 20 -120 -10 16.57 
UDCA 391.3 391.34 20 -120 -10 17.52 
DHCA 401.2 401.2 20 -90 -10   
a-MCA 407.3 407.3 20 -120 -10 15.93 
b-MCA 407.3 407.31 20 -120 -10 16.29 
CA 407.3 407.32 20 -120 -10 18.89 
w-MCA 407.3 407.33 20 -120 -10 15.93 
GLCA 432.3 432.3 20 -80 -10 19.77 
GUDCA 448.2 448.3 20 -130 -40 14.15 
GCDCA 448.3 448.31 20 -80 -10 17.72 
GDCA 448.3 448.32 20 -80 -10 18.28 
GCA 464.3 464.3 20 -80 -10 15.7 
TLCA 482.2 482.2 20 -130 -10 19.19 
TUDCA 498.2 498.3 20 -130 -60 13.66 
TCDCA 498.3 498.31 20 -130 -10 17.1 
TDCA 498.3 498.32 20 -130 -10 17.64 
THDCA 498.3 498.33 20 -130 -10 14.26 
T-a-MCA 514.3 514.3 20 -130 -10 10.81 
T-b-MCA 514.3 514.31 20 -130 -10 11.06 
TCA 514.3 514.32 20 -130 -10 15.08 
THCA 514.3 514.33 20 -130 -10 13.62 
              
d4-LCA 379.3 379.3 20 -90 -10 22.7 
d4-CDCA 395.3 395.31 20 -120 -10 20.83 
d4-DCA 395.3 395.3 20 -120 -10 21.13 
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d4-CA 411.3 411.3 20 -120 -10 18.86 
d4-GCDCA 452.4 74 20 -80 -40 17.73 
d4-GCA 468.4 74 20 -80 -40 15.71 
              
tlc query 482.2 80 20 -130 -60   
tdc query 498.2 498.2 20 -130 -60   
P lipid 
query 153 153 20 -130 -10   
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Qualifiers 
ID Q1 Q3 Dwell DP CE RT 
GLCA 432.3 74 20 -80 -40 20.59 
GCDCA 448.3 74.11 20 -80 -40 18.31 
GDCA 448.3 74.12 20 -80 -40 18.93 
GCA 464.3 74 20 -80 -40 16.03 
TCDCA 498.3 80.1 20 -130 -60 17.33 
TDCA 498.3 80.11 20 -130 -60 17.87 
T-a-MCA 514.3 80.1 20 -130 -60 10.68 
T-b-MCA 514.3 80.11 20 -130 -60 11.02 
TCA 514.3 80.12 20 -130 -60 15.12 
TLCA 482.2 80 20 -130 -60 19.57 
 
QTrap method file : Bile salts (MP).dam 
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Example Solvent Standard Chromatogram.
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For publication: 
Cleaned-up extracts were analysed using HPLC – mass spectrometry operated in 
multiple reaction monitoring (MRM) mode. 
Each sample (5 µl) was analysed using an Agilent 1260 binary HPLC coupled to an AB 
Sciex 4000 QTrap triple quadrupole mass spectrometer.  HPLC was achieved using a 
binary gradient of solvent A (Water + 5mM Ammonium Ac + 0.012% Formic acid) and 
solvent B (Methanol + 5mM Ammonium Ac + 0.012% Formic acid) at a constant flow 
rate of 600 µl/min. Separation was made using a Supelco Ascentis Express C18 150 x 4.6, 
2.7µm column maintained at 40°C.  Injection was made at 50% B and held for 2 min, 
ramped to 95%B at 20 min and held until 24 minutes.  The column equilibrated to initial 
conditions for 5 minutes. 
The mass spectrometer was operated in electrospray negative mode with capillary 
voltage of -4500V at 550°C.  Instrument specific gas flow rates were 25ml/min curtain 
gas, GS1: 40 ml/min and GS2: 50 ml/min 
Mass fragmentation was monitored as in the table below. 
Quantification was applied using Analyst 1.6.2 software to integrate detected peak areas 
relative to the deuterated internal standards. 
 
 
A portion of sample (50 mg accurately weighed) was taken into a tube along with 6 
ceramic beads, 1 ml of 70% v/v methanol and 25µl of 40 µg/ml d4-DCA and then 
homogenised for 30 seconds at 6000 rpm.  The slurry was centrifuged at 3000 rpm at 
4°C and the supernatant transferred to a new tube with the addition of 25 µl of 40 
µg/ml d4-CDCA. This was evaporated by centrifugal evaporation at 50° for 70 minutes to 
almost dryness and then made to 1 ml volume with 5% v/v methanol and addition of 25 
µl of 40 µg/ml d4-CA. 
The reconstituted sample was passed through a hydrophilic-lipophilic balance clean-up 
cartridge (Waters Oasis Prime HLB, 1cc, 30mg), washed with 1 ml of 5% methanol and 
eluted in 500 µl methanol and addition of 25 µl of 40 µg/ml d4-GCA and d4-LCA.  Of the 
internal standards added, d4-GCA was the primary reference internal standard with the 
others monitored as checks in the extraction procedure. 
The final sample was submitted for analysis my LC-MS/MS. 
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Appendix	3:	Metabolomics	results	for	urine	
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Appendix	4:	Metabolomic	results	for	faeces	
 
168 
 
Appendix	5:	Nanodrop	results	from	biliary	samples	
 
 
Table Appendix 1: Nanodrop results following DNA extraction from samples. GB = gallbladder sample, CBD = 
common bile duct 
 
 
  
Sample Number Nanodrop result (ng/ul) 
1GB 13.3 
2GB 20.6 
3GB 16.8 
4GB 86.3 
5GB 25.4 
6GB 26 
7GB 4.1 
8GB 18.2 
9GB 1.3 
10CBD 583.2 
11GB 11 
12GB 151.5 
13GB 9 
14CBD 21 
15CBD 2.7 
16CBD 1.2 
17CBD 3.4 
18CBD 14.3 
19CBD 1.6 
20CBD 51.4 
21CBD 58.1 
22GB 5.6 
23CBD 13.2 
23GB 26.8 
24CBD 16.3 
25CBD 20.3 
25GB 38.2 
26CBD 8.4 
26GB 22.8 
27CBD 2.1 
27GB 7.3 
28CBD 19.4 
28GB 57.2 
29CBD 4.7 
30GB 44.4 
31CBD 4.3 
32CBD 34.7 
32GB 24.5 
33CBD 27.9 
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